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Abstract 
In the human body there are tissues with limited regenerative potential, raising the need for 
cell-based regenerative therapies. The main objective of this thesis was to examine how 
tissue-specific extracellular matrix (ECM) affects the differentiation of human adipose-
derived stem/stromal cells (ASCs). The effects of incorporating milled, decellularized 
adipose (DAT) or cartilage (DCT) ECM particles on ASC lineage-specific differentiation in 
3-D cell aggregate cultures were explored. The results demonstrated that the addition of 
ECM improved differentiation for both adipogenesis and chondrogenesis. Analysis of 
adipogenic gene and protein expression indicated enhanced differentiation in the DAT+ASC 
aggregates relative to the DCT+ASC and ASC-alone groups at 14 days. Additionally, 
chondrogenic studies showed that incorporating DCT had a positive effect on collagen II 
deposition and late chondrogenic marker expression at 28 days when compared to 
DAT+ASC or ASC-alone groups. Overall, these findings support the further investigation of 
ECM as a cell-instructive platform for ASC differentiation.  
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Chapter 1  
1 Introduction 
In the emerging field of tissue engineering, many strategies have been developed to overcome 
obstacles related to tissue loss associated with injury or disease. Tissues with limited 
regeneration potential require stimulation to assist with the repair process in order to prevent scar 
tissue formation and promote recovery of function. Many studies exploit the use of bioactive 
materials and various cell types to stimulate in situ tissue formation. The concept that stem cell 
fate is regulated by the extracellular environment in vivo is well founded in research [1][2]. 
Recent studies suggest that cellular behavior of stem/stromal cells is mediated in part though 
biochemical and biomechanical interactions with the extracellular matrix (ECM), as well as 
through other environmental cues (e.g. oxygen tension) and signaling with surrounding cells 
[3][4].  
The ECM is a complex 3-dimensional network of proteins, proteoglycans, and glycoproteins that 
are tissue-specific in structure and composition [3]. The ECM is known to influence cellular 
responses such as cell survival, development, shape, and migration through interactions with 
adhesion molecules, binding proteins and various enzymes [4][5]. Physical and biomechanical 
cues such as matrix architecture and surface chemistry also play an important role in mediating 
cellular functions [6]. A large area of tissue engineering and cell-based therapy research is 
focused on designing novel scaffolds and biomaterials to mimic the ‘tissue-specific niche’ and 
simulate the biomechanical and biochemical cues present in vivo in order to stimulate 
regeneration [5][7][8].  
For the development of cellular therapies, adipose tissue represents an attractive source of adult 
mesenchymal stem/stromal cells (MSCs) [9]. Adipose-derived stem/stromal cells (ASCs) can be 
isolated from the stromal vascular fraction (SVF) of digested adipose tissue using established 
procedures. The stem/stromal population is selected through serial passaging of the tissue culture 
polystyrene (TCPS)-adherent cell population [10]. ASCs are a promising cell source for 
regenerative therapies due to their relative abundance and ease of access when compared with 
other MSC sources, such as bone marrow-derived MSCs [9]. Further, ASCs are a heterogeneous 
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cell population that includes multipotent adult stem cells, capable of differentiating along the 
adipogenic, chondrogenic, and osteogenic lineages, as well as displaying cell surface markers of 
the neuronal, endothelial, and hematopoietic lineages [11][12]. ASCs may be incorporated into 
scaffolds, where they assist in modulating the cell niche by stimulating the recruitment and 
differentiation of host cells through paracrine signaling [10]. 
1.1 Project Motivation 
The ECM is a key component of the tissue-specific natural microenvironment for cells. 
Therefore ECM-derived biomaterials are of interest as stem cell delivery vehicles, to improve 
cell attachment and survival in vivo [13][14]. The heterogeneity of the ECM composition within 
various tissues provides a rationale for applying a tissue-specific approach to bio-scaffold design. 
The selection of naturally derived, tissue-specific scaffolds comprised of ECM as a platform for 
tissue regeneration is well supported, as it is recognized that cells exchange signals with both 
neighboring cells and the surrounding matrix [15][2][16]. An ideal scaffold should mimic the 
properties of the native tissue, supporting the rationale for the use of tissue-specific scaffolds. 
Many approaches target tissue decellularization as a method of obtaining tissue-specific ECM 
from sources such as heart, adipose tissue, cartilage, bone, kidney and lung [9], [17]–[21]. 
However, limited research has been done to date to compare the effects of tissue-specific ECM 
on the lineage-specific differentiation of MSCs [22][18][9].  
1.2 Project Rationale 
To study the effects of tissue-specific ECM on the adipogenic and chondrogenic differentiation 
of human ASCs in vitro, culture conditions must allow for adipogenesis and chondrogenesis to 
occur in their preferred environment, which is a 3-dimensional (3-D) culture with high cell 
density [23][24][25]. A high cell density is often achieved by culturing ASCs clustered in an 
aggregate, often referred to as a pellet culture. Incorporating decellularized ECM sourced from 
adipose tissue or cartilage into the cell aggregate cultures will give insight into the potential 
importance of using tissue-specific ECM to guide differentiation and/or to act as a natural 
scaffold for the regeneration of adipose or cartilage tissue. For this reason, decellularized adipose 
tissue (DAT) and decellularized cartilage tissue (DCT) were lyophilized, milled, and 
incorporated into 3-D aggregates fabricated by centrifuging a suspension of ASCs and ECM 
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particles. In vitro cell culture studies were conducted to explore adipogenesis and 
chondrogenesis of ASCs in the cell-ECM aggregates. The level of adipogenic and chondrogenic 
differentiation within the various aggregates was assessed in both proliferation medium and 
differentiation medium to examine the potential inductive effects of the ECM on ASC 
differentiation. ASCs were also cultured in cell aggregate cultures without ECM as a control.  
1.3 Hypothesis 
With support from the literature that tissue-specific ECM has the ability to influence cellular 
behaviors, it was hypothesized that the ECM will stimulate ASCs to differentiate towards the 
lineage specific to that of the native tissue. Therefore, cells cultured with DAT particles will 
demonstrate an increased tendency for differentiation towards the adipogenic lineage and the 
ECM will have an inductive effective on adipogenic differentiation under proliferation 
conditions. Similarly, ASCs cultured with DCT particles will be induced towards the 
chondrogenic pathway. It was expected that differentiation levels will be higher in all aggregates 
containing ECM, and that differentiation towards the adipogenic lineage will be highest in the 
samples combining DAT with adipogenic medium. Likewise, chondrogenic differentiation was 
expected to be highest when ASCs were cultured with DCT in chondrogenic medium.  
1.4 Specific Objectives  
The objectives of this Master’s project were:  
1) To establish methods for decellularizing porcine auricular cartilage based on existing 
decellularization protocols in the literature.  
2) To refine protocols for cryo-milling the DAT and DCT, and to characterize the particles 
using SEM and dynamic light scattering. 
3) To conduct in vitro cell culture studies to investigate adipogenesis and chondrogenesis in 
cell aggregates comprised of (i) ASCs and DAT (ii) ASCs and DCT, and (iii) ASCs 
alone, cultured in both differentiation and proliferation media. 
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Chapter 2  
2 Literature Review 
2.1 Adipose-derived Stem/Stromal Cells (ASCs) 
Research conducted by Friedenstein et al. identified some of the first reported evidence of tissue 
culture polystyrene (TCPS)-adherent bone marrow-derived mesenchymal stem/stromal cells 
(BMSCs) that were capable of expansion and differentiation towards osteogenic lineages [26]. 
Further examination led to the identification of stem/stromal cells within other adult tissues, and 
since this time mesenchymal stem/stromal cells (MSCs) have been discovered within many 
human tissues [27]–[29]. This work revolutionized modern cell therapy strategies as MSCs 
became more readily available, and could be expanded in culture and differentiated towards 
multiple lineages [30].  Adipose-derived stem/stromal cells (ASCs) are attractive as a cell source 
due to their relative abundance, the ease of access to adipose tissue (fat) with minimal discomfort 
to patients, and the larger cell yield when compared to BMSC populations [29]. While BMSCs 
have been studied extensively, limitations to using this cell type include low yields (1 BMSC in 
every 3.4 x 104 bone marrow nucleated cell population) and painful collection procedures [31]. It 
is for these reasons that ASCs are being extensively researched in the field of regenerative cell 
therapies.  
Another benefit of ASCs is the potential to be an autologous stem/stromal cell source for 
patients, as the cells are easily obtained from subcutaneous fat stores within the body. Cellular 
procurement may be accomplished through minimally invasive procedures such as lipoaspiration 
[29] or from excess tissues collected during elective breast or abdominal reduction surgeries 
[32]. There are varying methods of ASC isolation, but common protocols involve enzymatic 
digestion and centrifugation steps to yield the stromal vascular fraction (SVF). Current views of 
ASCs suggest that they co-exist with resident endothelial cells and pericytes within the 
perivascular niche in vivo. After isolation, the SVF contains a heterogeneous mixture of 
endothelial progenitor cells, pericytes, fibroblasts, blood cells, smooth muscle cells, 
macrophages, pre-adipocytes, and MSCs [33]–[35]. Expansion of the heterogeneous SVF aids in 
the selection of adherent cell populations to yield a purer ASC culture. Donor variability, 
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isolation procedures, growth conditions, and sites of tissue harvesting have been noted as 
potential reasons for differences seen within varying ASC populations [36]–[38].  
Recent studies found that an increased donor age, increased body mass index (BMI), and reduced 
donor health have been linked to decreased proliferation and differentiation capacities and an 
increase in cell senescence markers [39]–[41]. Interestingly, donor depot has also been linked to 
differences in ASC characteristics [42]. Studies by Schipper et al. found that the upper arm and 
medial thigh depots consistently yielded ASCs with a greater proliferation and differentiation 
capacity when compared to the depots of the abdomen or trochanter [42]. Russo et al. reported 
that adipogenesis was enhanced in ASCs isolated from subcutaneous, pericardial, and thymic 
remnant adipose tissue, while osteogenic differentiation levels were upregulated in ASCs 
sourced from the omentum [43]. Other potential differences have also been noted between male 
and female donors, however more research is needed to confirm these findings [43], [44]. These 
findings highlight the need for larger studies to assess significant differences between donor 
gender, depot site, age, and BMI and the effect these factors may have on ASC proliferation and 
differentiation capacity and ASC immunophenotypes.  
2.1.1 ASCs in Regenerative Tissue Engineering 
According to Gimble et al., ASCs retain the ability to give rise to genetically identical daughter 
cells through the process of mitotic division [38]. ASCs are also capable of differentiation 
towards cells of the mesodermal lineage, including adipocyte, chondrocyte, osteoblast, myocyte, 
and peripheral nerve lineages [29], [45]. Based on yields obtained from isolations, expected 
cellular demands for therapeutic applications can require approximately 109 stem cells [46]. 
ASCs have the potential to meet that need, making them promising sources for musculoskeletal 
research applications. Comparatively, reports on ASC isolations suggest that cell yields can 
reach 40 times more than BMSCs [29], [47], [48].  
ASCs have the ability to be cultured in various conditions such as 2-D and 3-D cultures, under 
normoxic and hypoxic conditions, static and dynamic cultures, and under different media 
formulations [45]. This is beneficial from a culturing perspective as methods can be altered to 
examine cellular behavior from a multitude of perspectives in culture. Due to the ability of ASCs 
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to be cultured under various conditions, cultures may be tailored to conditions seen in a specific 
tissue of interest in vivo, including in diseased states.  
ASCs are also capable of secreting paracrine factors that can modulate wound healing [49]. A 
variety of growth factors such as platelet-derived growth factor (PDGF), vascular endothelial 
growth factor (VEGF), as well as cytokines such as interleukin-10 (IL10) and prostaglandin E2 
(PGE2) have been shown to be secreted by ASCs within wound healing sites [50]–[52]. 
Evidence also suggests that ASCs are capable of modulating macrophage behavior and recruiting 
cells to promote tissue remodeling [53]. Transplantation of ASCs in vivo demonstrates minimal 
evidence of immune rejection and as a result, allogeneic ASCs may hold potential for use in cell 
therapy applications [46].  
2.1.2 Immunophenotype of ASCs 
The International Society for Cellular Therapy (ISCT) and the International Federation for 
Adipose Therapeutics and Science (IFATS) have defined a set of parameters with the intention 
of characterizing ASCs. The following criteria were proposed for the characterization of ASCs: 
(1) plastic-adherent, (2) express the standard immunophenotypic profile (Table 2.1), and (3) 
maintain multipotency towards the adipogenic, osteogenic, and chondrogenic lineages [54].  
ISCT and IFATS suggest that immunophenotype analysis should include at least two primary 
positive markers, one secondary positive marker, two primary negative markers, and one 
secondary negative marker when characterizing ASCs [54]. Positive expression of primary 
markers should be greater than 80% but less than 2% for primary negative markers. Additionally, 
cell viability should be greater than 90% [54]. It is worth noting that some discrepancies have 
been published in terms of expression levels of some markers between culture conditions and 
passage number, highlighting the need for guidelines for characterizing ASC populations, as well 
as standardization of isolation and culture methods. In addition, studies have noted that 
immunophenotypes of ASCs may be altered in 2-D cultures when compared to cells found in 
vivo or when cultured in 3-D cultures [46]. 
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Table 2.1 ASC Immunophenotype 
Marker type Antigen  
Primary positive (>80%) CD90 (Thy-1) 
CD105 (endoglin) 
CD73 (ecto-5’-nucleotidase) 
CD44 (hyaluronic acid receptor) 
CD29 (β1-integrin) 
CD13 (aminopeptidase-N) 
CD34 (progenitor associated marker)* 
CD146 (melanoma cell adhesion molecule (MCAM))* 
Secondary positive  CD10 (nephrilysin) 
CD26 (dipeptidyl peptidase-4) 
CD48d (α4-integrin)* 
CD49e (α5-integrin) 
CD36 (fatty acid translocase) 
Primary negative (<2%) CD31 (platelet endothelial cell adhesion molecule (PECAM)) 
CD45 (leukocyte-common antigen-antigen D related) 
Secondary negative  CD3 (T-cell co-receptor) 
CD11b (α6-integrin) 
CD49F (αM-integrin) 
CD106 (vascular cell adhesion protein 1 (VCAM-1)) 
*Variable levels of expression 
2.1.3 Adipogenesis 
 It is known that ASCs are capable of differentiating along multiple pathways, including the 
adipogenic pathway [29]. In general, ASCs undergoing adipogenesis prefer close cell-cell 
contact, suggesting that a high cell density is preferred prior to differentiation towards this 
lineage. ASCs have been shown to differentiate both on 2-D TCPS and on 3-D scaffolding 
materials [32]. Glucocorticoid agonists such as hydrocortisone and dexamethasone (DEX) 
initiate the induction of ASCs toward the adipogenic pathway (Figure 2.1) [55]. Presence of 
hydrocortisone and DEX, along with supra-physiological insulin concentrations, initiate a 
signaling cascade [56], [57]. This in turn activates receptors in pre-adipocytes to stimulate the 
activation of early transcription factors CCAAT/enhancer-binding protein-β (C/EBPβ) and 
CCAAT/enhancer-binding protein-δ (C/EBPδ) [58]. This causes the upregulation of the primary 
transcription factors peroxisome proliferator activated receptor-ϒ (PPARϒ) and 
CCAAT/enhancer-binding protein-α (C/EBPα) [55], [57]. Cell proliferation is inhibited by the 
activation of C/EBPα while sensitivity to insulin is maintained. A positive feedback loop ensues 
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between PPARϒ and C/EBPα to maintain increased expression as the cells accumulate lipid 
during maturation and move closer to terminal differentiation [59], [60]. Adipocyte-specific 
genes such as lipoprotein lipase (LPL), glucose transporter-4 (GLUT4), glycerol-3-phosphate 
dehydrogenase (GPDH) and insulin receptors are all upregulated, driving the cells to further 
maturation and lipid accumulation [55].  
 
Figure 2.1 Transcriptional control of adipogenesis. 
There is a delicate balance of factors that mediate adipogenesis along the transcriptional 
signaling cascade. Fatty acids and prostaglandins act as ligands or precursor ligands for PPARϒ 
or may help to induce the adipogenic factors C/EBPβ and C/EBPδ [61]–[63]. Glucocorticoids 
also promote adipogenesis through activating C/EBPδ and PPARϒ expression [64], [65]. 
Nuclear co-activated receptors, like PPAR binding protein, work through PPARϒ to promote 
adipogenesis [60]. Insulin-like growth factor-I receptors (IGF-IRs) also function to increase 
insulin sensitivity of the cells, driving maturation. Conversely, factors such as wingless-related 
integration site (Wnt) signaling, transforming growth factor-β (TGF-β), tumor necrosis factor-α 
(TNF-α), and interleukins (IL-1, IL-6, IL-11) inhibit adipogenesis through inhibition of PPARϒ 
and CEBPα [55], [57], [66]. Upregulation of adipogenesis in vitro often includes the addition of 
supplements such as insulin, DEX, hydrocortisone, troglitazone, and 3-isobutyl-1-
methylxanthine (IBMX) to serum free media [67], [68]. 
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2.1.4 Chondrogenesis 
ASCs have the ability to differentiate towards the chondrogenic lineage, however, this cannot be 
accomplished in 2-D on TCPS. The cells require the high cell density and close cell-cell contact 
that can only be accomplished in 3-D cultures [69], [70]. It is for this reason that pellet cultures 
are often used during chondrogenesis [71]. This culture format mimics the mesenchymal 
condensation process that occurs during chondrogenesis in vivo and allows the cells to initiate 
differentiation towards the chondrogenic pathways [72].  
Sex-determining region Y-related high motility group box 9 (SOX9) is an important transcription 
factor in chondrogenesis [73]. Transcription of SOX5 and SOX6 is induced by SOX9, which act 
in turn to enhance SOX9 activity and maintain chondrogenic phenotypes, preventing 
hypertrophy [74]. SOX9 induces chondrogenesis by upregulating cartilage-matrix specific genes 
to help maintain pre-chondrocyte phenotypes [75]. Chondrogenic factors such as TGF-β and 
bone morphogenic proteins (BMPs) are key to initializing the chondrogenic signaling cascade 
that leads to the condensation process [76]–[79]. ASCs begin to differentiate into chondroblasts 
following condensation. In this stage, the cells are highly proliferative and begin matrix 
deposition of collagens II, IX, XI, and aggrecan (Figure 2.2) [78], [80]. Subsequently, cartilage 
oligomeric matrix protein (COMP) is upregulated while collagen I is downregulated [71], [72], 
[59]. It is for this reason that ratios of collagen II:collagen I are often compared using 
immunohistochemistry (IHC) to assess chondrogenesis.  
Late stages of chondrogenesis may see chondroblasts become hypertrophic chondrocytes, where 
collagen X is upregulated and calcification begins [80]. This signals terminal differentiation of 
chondrogenesis and marks the beginning of osteo-chondrogenesis. Runt-related transcription 
factor 2 (RUNX2) is upregulated during this time [81]. Since none of this can occur without the 
initial condensation process that triggers upregulation of SOX9 and cartilage-specific ECM 
synthesis, it can be stated that chondrogenesis is highly dependent not only on transcriptional 
control but may be partially controlled by cells responding to signals within their immediate 
surroundings, including the ECM [72], [73], [75], [82].  
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Figure 2.2 Transcriptional control of chondrogenesis. 
2.2 The Extracellular Matrix (ECM) 
Tissue loss acquired through disease or trauma poses problems where tissue regeneration is 
limited due to scar tissue formation and/or the loss of function in the afflicted area. This loss of 
function can impact the health and well-being of the patient. This raises the need for the 
development of cell-based therapies for connective tissue loss and is a major area of research in 
tissue engineering. In the field of tissue engineering, there is growing evidence to support the 
application of cell-based therapies to promote the regeneration of soft connective tissues in order 
to restore structure and function following tissue damage [29], [82]. Recent studies have 
suggested that the proliferation and differentiation of stem/stromal cells can be mediated through 
interactions with the ECM [6], [83]–[85]. Therefore, cell-based approaches that combine 
stem/stromal cell-based therapies with biomaterials have become a highly researched field of 
study.  
Tissues within the body are comprised of cells and an extracellular matrix that is comprised of an 
intricate network of proteins and polysaccharides [86]. The macromolecules within the ECM are 
locally secreted by the cells and assembled and organized into tissue-specific structures [3], [5], 
[87]. There is a dynamic relationship that exists between the cells and the ECM. The ECM is 
active in regulating cellular behaviors and processes such as attachment, proliferation, and 
survival [88]. Likewise, as the cells within the niche respond to their environment, they secrete 
factors that induce alterations or remodeling of their surroundings [88], [89]. For example, cells 
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can secrete matrix metalloproteinases (MMPs) that enzymatically degrade the ECM to allow for 
cellular migration and release of ECM-bound molecules [90], [91]. This dynamic state highlights 
the interdependent relationship of cells and the ECM, supporting the rationale for incorporating 
ECM-based biomaterials into therapeutic strategies. 
 There are two main types of ECM, the basement membrane/basal lamina and connective tissue 
ECM [92], [93]. The basal lamina is a thin, highly bioactive structure that is often associated 
with various pathologies such as epidermolysis bullosa [94]. Connective tissue ECM is very 
important in cell regulation as it provides both structural and chemical cues to the cells [95]. The 
cells within a tissue help to create and maintain the integrity of the ECM by constant remodeling 
in response to stimuli [96].  
The main macromolecules secreted by the cells within the matrix are: (1) fibrous proteins that 
include collagen and elastin, (2) glycosaminoglycans (GAGs), (3) proteoglycans, and (4) 
glycoproteins [97]. The specificity of the matrix is determined by the relative amounts of the 
different macromolecules within the matrix and the organization of those components to give 
tissue-specific structures and functions. Regulation of cellular behavior is achieved by 
interactions with cells and the surrounding matrix. Cell surface receptors called integrins bind 
cells to the ECM and can trigger a signaling cascade via the cytoskeleton in response to 
mechanical stimuli [86]. Functions such as cell shape, survival, proliferation, migration, and 
tissue cohesion may be determined, in part, by the ECM [89]. For this reason, it is important to 
have an understanding of the components of the cell-secreted ECM. This section will focus on 
the main types of macromolecules present in the ECM. The specific structure and composition of 
adipose tissue and cartilage ECM will be discussed in detail in Sections 2.4.1 and 2.5.1 
respectively.  
2.2.1.1 Fibrous Proteins 
Fibroblasts synthesize collagens, GAGs, and glycoproteins and are responsible for a large 
majority of matrix production and remodeling in many tissues in the body [90]. In adipose tissue, 
adipocytes and pre-adipocytes are responsible for the majority of ECM production, however 
other cells types such as fibroblasts, vascular cells, and macrophages can be involved in matrix 
synthesis and modification [98]–[101]. In comparison, cartilage ECM is deposited mainly by 
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chondrocytes [102], [103]. Proteins embedded within the matrix act as sites for cell adhesion and 
signaling. Collagen plays a major role within the ECM and is one of the main components that 
make up these complex structures [104].  
Collagen fibers impart structural integrity, organization, strength and resilience to the ECM and 
therefore play an important role in cell attachment, growth and differentiation through receptor 
mediated signaling [105]. Collagens are the most abundant fibrous proteins within the interstitial 
ECM, comprising 20-40% of total protein within the body. This family of structural and 
bioactive proteins functions to regulate cell adhesion, support cellular migration, and direct tissue 
development [106]. The right-handed triple helix comprised of three α-chain subunits is a 
defining characteristic of collagen (Figure 2.3a) [104]. These α-chain subunits are stabilized by 
hydrogen bonds and are each encoded by a unique gene. Within these long polymers, there are 
repeated amino acid sequences of (Gly-X-Y) where approximately 30% of the time X is proline 
and Y is hydroxyproline [104]. To date, 28 different types of collagen have been identified and 
can be classified as either (1) fibrillar, (2) fibril associated collagen with interrupted helices 
(FACIT), (3) short chain, (4) basement membrane, or (5) microfibrillar [105]. Each of these 
collagen types is associated with unique amino acid sequences and conformational structures that 
give individual functions, such as basement membrane collagens like collagen IV [97]. The α-
chains within collagen IV lack a glycine residue in every third amino acid, allowing the chains to 
be covalently crosslinked and assembled into flexible sheet-like structures [105], [104]. 
The ability of tissues to deform from mechanical stimuli and recoil back to their original state 
can be attributed to the properties of the insoluble fibrous protein, elastin (Figure 2.3) [107]. 
Elastin is comprised of multiple tropoelastin monomers that are crosslinked by lysyl oxidase to 
form desmosine residues (Figure 2.3b) [108], [109]. Non polar amino acid residues comprise 
much of these monomers, which are rich in proline and lysine [110]. Elastin and collagen are 
often in close association, as the stretch of elastin is limited by the tight associations with 
collagen fibrils [106].  
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Figure 2.3 Representative images of (a) collagen, (b) elastin, (c) fibronectin, and (d) 
laminin. Images adapted from Lange Histology and Cell Biology, 2010 [111]. 
2.2.1.2 Glycosaminoglycans 
GAGs are comprised of repeating disaccharide units, where one of the two sugars is always an 
amino sugar (N-acetylglucosamine or N-acetylgalactosamine), and the other sugar is usually an 
uronic acid (glucuronic or iduronic). These sugars typically contain carboxyl or sulphate groups, 
and create an anionic charge [97]. GAGs may be further subcategorized into four main types, 
distinguished by the sugars, the linkage of those sugars, and the number and location of the 
sulphate groups. The main types of GAGs are: hyaluronan, chondroitin sulphate, heparan 
sulphate, keratin sulphate, dermatan sulphate and heparin, which may be found in varying 
amounts within different tissues [97], [106]. Hyaluronan is found in skin and load bearing joints, 
and chondroitin sulphate is most commonly found in ligaments, tendons, and cartilage [112]. 
GAGs aid in resisting compressive forces through their negative charges. The highly negative 
nature of GAGs attracts ions such as Na+, allowing the matrix to become hydrated [106], [112]. 
The osmotic pressure created, such as that within the knee joint, allows the tissue to withstand 
large compressive forces [97], [113]. For example, hyaluronan is a type of GAG that is found in 
load-bearing joints that not only aids in resisting compressive forces, but also contributes to joint 
lubrication [97]. With the exception of hyaluronan, GAGs are covalently attached to proteins to 
create proteoglycans [97]. 
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2.2.1.3 Proteoglycans  
Proteoglycans consist of polysaccharide chains bound to a protein where at least one of the sugar 
side chains is a GAG, thus distinguishing them from glycoproteins [114]. Proteoglycans may 
contain more sugars by weight (up to 95%) when compared to glycoproteins, and may have 
many long unbranched GAG chains [115], [116]. Proteoglycans are remarkably diverse, 
possessing a variety of structures and functions. Aggrecan, for example, is one of the most 
important ECM proteins in cartilage that aids in the load distributing properties that are present 
in weight-bearing joints [114], [117]. Proteoglycans also promote the rapid diffusion of nutrients, 
metabolites and cytokines by aiding in the hydration of the ECM [118].  
Proteoglycans also play a role in chemical signaling between cells. They attach to cell surfaces 
and bind to fibrous collagens or fibronectin on the ECM to act in a similar manner to cell-
adhesion molecules [117]. As most proteoglycans are extracellular in nature, they have the 
ability to affect signaling cascades and influence intracellular events [119]. Not only do the 
molecules function as structural components of the ECM, but they have the ability to sequester 
and present many growth factors [117]. 
2.2.1.4 Glycoproteins 
Glycoproteins contain many short, branched oligosaccharide chains and are 1-60% carbohydrate 
by weight [97]. For example, fibronectin is an important matrix glycoprotein that it is involved 
with cellular adhesion through integrins. In addition, fibronectin is thought to be involved in 
directing organization of the ECM [106]. The multi-domain structure of fibronectin plays an 
active role in ECM assembly by forming a bridge between cell surface receptors such as 
integrins, and collagens, proteoglycans, and other focal adhesion molecules (Figure 2.3c) [115]. 
Various binding domains present on the fibronectin backbone bind cells as well as molecules 
such as fibrin, heparin, and collagens [115]. As another example, laminin is the most abundant 
glycoprotein in the basement membrane and is able to bind various receptors on the cell surface 
to elicit cellular responses [93]. Laminins are proteins that form sheet-like networks within the 
basal lamina of the ECM (Figure 2.3d) [97]. They are known to contribute to the structure of the 
ECM and modulate cellular functions such as adhesion, migration, resistance to apoptosis, 
stability of phenotype, and differentiation [115].  
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2.2.2 Extracellular Matrix-Derived Scaffolding Materials 
Cell types may vary widely from one type of tissue to another, but the ECM of various tissues 
contains the same base components. Knowing this, research has centralized around the idea of 
tissue-engineered biomaterials and scaffolds as a method for synthesizing tissue constructs [6], 
[82], [120], [121]. Scaffold design is a major area of research as the scaffold plays an important 
role in tissue repair. An ideal 3-D scaffold should mimic the properties of the native tissue but as 
this is extremely challenging to achieve, general guidelines for scaffolds include [122]:  
(1) The scaffold must promote cell-biomaterial interactions, adhesion, and ECM deposition; 
(2) The scaffold must permit transport of gases, nutrients, and regulatory factors as necessary 
for cell survival, proliferation, and differentiation; 
(3) The scaffold must biodegrade at a controllable rate that approximates the rate of tissue 
regeneration under culture conditions of interest; 
(4) The scaffold must not elicit a chronic inflammatory response or toxicity in vivo. 
Through the use of rationally-designed scaffolds, tissue engineering strategies have demonstrated 
the ability to improve tissue repair in vivo [32]. It has been established that the ECM plays a vital 
role in the support and regulation of cellular behavior, providing the rationale for using ECM as 
a scaffold for tissue repair. In theory, ECM-based biomaterials can meet the above requirements, 
and may potentially provide cell-instructive guidance for tissue repair.  
2.2.2.1 Tissue-Specific Scaffolds for Tissue Engineering  
As it has been previously stated, all tissues have their own tissue-specific composition and 
structure that distinguishes them from other tissues within the body. It is this rationale that leads 
to the belief that tissue therapies should use materials to mimic the native ECM of that tissue as a 
tissue-specific approach is hypothesized to be superior to a non-specific approach [3]. 
Replicating the ECM of the native tissue for regenerative purposes would require an in-depth 
knowledge of the native ECM composition of a particular tissue. Even if replicating the 
components was trivial, structural arrangement would still pose a problem that hinders “bottom-
up” strategies to recapitulate the native microenvironment. As an alternative approach, tissue 
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decellularization provides a straightforward method in which tissue samples are treated to 
remove cellular components and extract the tissue-specific ECM [82].  
Decellularized tissues have been used in their intact form but the lack of a tunable geometry can 
pose a potential limitation for some applications [123]. For this reason, the ability to manipulate 
the various properties of the scaffolds is an area of significant research interest. The use of 
lyophilization and milling to create fine powders and/or enzymatic digestion creates the potential 
to manipulate the ECM into desired architectures and formats [1], [124], [125]. Hydrogels, 
foams, microcarriers, sheets, powders, and injectable pastes have been developed, with varying 
properties including stiffness, porosity, and architecture [1], [126]–[130]. 
The use of decellularized materials is a promising strategy in tissue engineering. Depending on 
processing, the decellularized tissue may provide a complex array of chemical and mechanical 
properties through the retention of ultrastructure and signaling proteins that is challenging to 
mimic through the use of synthesized biomaterials [18]. This natural, tissue-specific scaffold can 
then be used in its intact format or fabricated and manipulated into various forms depending on 
the target application [126], [131], [95], [132], [133]. 
2.3 Tissue Decellularization 
Decellularization involves the mechanical, chemical, and/or enzymatic processing of tissues of 
the body to remove cellular components while ideally maintaining the structural and functional 
integrity of the proteins comprising the ECM. In turn, this will minimize the potential for 
immune rejection [82]. Advantages of these methods include that the scaffolds may retain the 
native ECM architecture, leading to similar biomechanical properties as seen in vivo. It is also 
possible that cell adhesion ligands may still be intact, thereby improving biochemical 
interactions [134]. This framework provides a structural lattice for cellular migration and tissue 
organization in a way that is difficult to replicate artificially. In the past, decellularization of both 
whole organs and tissues has been accomplished [82].  
Tissue decellularization has been accomplished by perfusing solutions through existing 
vasculature of the tissue, as seen in lung or heart decellularization, or by agitation of tissue 
blocks or sections immersed in solutions [18], [19]. While perfusion decellularization may 
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provide the advantage of better retaining the original shape/structure of the tissues, this requires 
the vascular network of the tissue to be intact. Cannulation is also technically challenging and 
may lead to rupture of blood vessels. Not all tissues are extensively vascularized however, and so 
immersion and agitation in fluids may be required for proper decellularization. The most 
common practices involve the use of acids and bases, hypo- and hypertonic solutions, detergents, 
alcohols, enzymes, and mechanical stimulation for decellularization [135]. 
2.3.1 Chemical Decellularization Methods 
Acids and bases are commonly used to either cause or catalyze degradation of biomolecules. 
Varying concentrations of acetic acid are commonly used to remove collagens, thereby reducing 
ECM strength without disrupting sulphated GAGs [135]. Dermal samples are often subjected to 
harsh bases to remove hair in early decellularization. However, treatment with bases is typically 
quite harsh and may eliminate growth factors and decrease ECM structural properties by 
cleaving collagen fibrils, which is a downside to using bases in decellularization practices [135]. 
Hypertonic and hypotonic solutions can be most effective when alternated through several cycles 
to rinse cell residue from within the tissues following cells lysis [82], [135]. The combination of 
the two creates osmotic stress, resulting in cell lysis. Hypotonic saline solutions are used to lyse 
cell membranes without causing major changes to the ECM, and can also help to dissociate DNA 
from proteins within the cells [82], [136].  
Detergents are effective in removing cellular material by solubilizing cell membranes and 
dissociating DNA from proteins [135]. While detergents are effective at removing cellular DNA, 
they are also known for disrupting and dissociating proteins in the ECM, as evidenced by their 
use in proteomics [137], [138]. Detergents can be broadly separated into three categories: (1) 
ionic, (2) non-ionic, and (3) zwitterionic [135]. The most commonly used detergents in 
decellularization practices are Triton X-100, sodium dodecyl sulphate (SDS) and 3-[(3-
cholaminopropyl)dimethylammonio]-1-propanesulfonate (CHAPS). Triton X-100 (non-ionic) 
can be effective at removing cellular residues from some dense tissues, like cartilage. Like 
Triton, SDS (anionic) is also widely used for decellularizing thick or dense tissues and has 
demonstrated superior removal of cellular DNA when compared to Triton X-100. However, SDS 
is also much more disruptive to the ECM and is known to remove important growth factors, 
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although the effects may be highly tissue dependent [135]. For this reason, sodium 
deoxycholates have been explored as an alternative where retention of ECM growth factors is 
important [139], [140]. CHAPS is a zwitterionic detergent that is most effective at removing 
cellular material from thin tissues such as lung, while better maintaining the ultrastructure of the 
ECM [82], [135]. Care must be taken to remove remaining detergents from tissues, as 
cytotoxicity is possible even in small concentrations [20], [135]. Removing anionic detergents 
such as SDS can prove to be more difficult than non-ionic detergents [135], [136].  
Alcohols such as isopropanol, glycerol, and ethanol dehydrate tissues and lyse cells, making 
them useful reagents in decellularization protocols. Alcohols have been shown to remove 
intracellular lipids, making them very effective in adipose decellularization protocols [131]. 
Alcohols are also used as a fixative in histology practices and to precipitate out proteins so 
evaluating the effects of alcohols on the ECM is important in order to avoid excess damage to 
the ECM [141].  
Other solvents such as acetone and tributyl phosphate (TBP) are also used as chemical agents for 
decellularization. Acetone can be used to remove lipids, but is also known to produce stiffer 
scaffolds by crosslinking the ECM [142]. TBP is an organic solvent that appears to be 
particularly good at removing cellular contents from dense tissues, such as tendon [136], [143]. 
While there have been various reports on the effects it has on the biochemical and mechanical 
properties of the ECM, TBP has shown potential as a decellularizing agent over either Triton X-
100 or SDS in dense tissues for retention of mechanical properties while removing cellular 
contents [135], [139], [140]. 
Enzymes such as trypsin, lipase, collagenase, and various nucleases (RNases and DNases) have 
been used in various protocols to disrupt proteins, remove cell residues, and digest nucleic acids 
[131], [135]. Enzymes may be used to extract specific components, but use of enzymes alone is 
not sufficient for decellularization. Additionally, non-enzymatic agents such as chelators and 
serine protease inhibitors are used to aid in cell dissociation from the ECM and minimize ECM 
damage. Antibiotics and antimycotics are also used to minimize microbial contamination during 
decellularization and are often added to many decellularization solutions [135], [144]. 
  
19 
 
2.3.2 Mechanical Decellularization Methods 
In many cases, mechanical methods must be used in conjunction with chemical decellularization 
to achieve effective decellularization. Freeze/thaw cycles are often used to lyse cells within 
tissues [135]. Multiple freeze/thaw cycles may be used, with subsequent washes to remove 
cellular contents [135]. Some studies have shown that temperature disruption may also reduce 
adverse immune responses in vascular ECM scaffolds [145]. Cellular contents can also be 
removed through the forces associated with agitation in fluids, gravity separation of lipids 
through centrifugation, mechanical abrasion, and tissue compression [131], [95], [135]. These 
methods have proven particularly effective, and may cause less disruption to the ECM than 
chemical agents. In relatively acellular tissues, such as articular cartilage, freeze/thaw cycles and 
pulverizing the tissue through the use of cryogenic milling have been used as the main forms of 
decellularization [22], [144]. Limitations of these methods include that freeze/thaw cycles have 
limited efficacy on load bearing and mechanically robust tissues, and that pulverizing the tissue 
disrupts ECM architecture and has the potential to damage or eliminate important matrix proteins 
[133], [146].  
2.3.3 Optimizing Methods for Tissue Decellularization 
Tissues are comprised of both cellular material and ECM but the physical and chemical bonds 
vary in degrees of compactness [82]. The ECM must be adequately disrupted for the cellular 
materials to be removed, while minimizing the disruption to the tissue so as to maintain 
biomechanical and biochemical components of the ECM. The decellularization process must also 
leave the tissue free of added chemicals, such as detergents, if the ECM is to retain the native 
composition and limit toxicity in vitro or in vivo [6], [82]. Protease inhibitors may be used to 
preserve the ECM during the decellularization process [82], [147]. 
The specificity of the ECM for each tissue raises the need for unique decellularization practices 
with investigation into optimal methods for each tissue. Often, both chemical and mechanical 
methods are combined in decellularization protocols to deal with the varying requirements for 
tissue-specific decellularization [9], [82]. To test the effectiveness of decellularization, Masson’s 
trichrome, DAPI nuclear staining, and DNA quantification, such as using the PicoGreen® 
dsDNA assay, are often used to measure cellular remnants. The use of ECM as a cell-instructive 
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therapy has been a large area of research in recent years. As such, recent studies have 
investigated the results of ASCs seeded on tissue-specific decellularized ECM scaffolds in the 
form of intact scaffolds, powders, hydrogels, foams, electrospun fibres and sheets for the 
purposes of tissue engineering [32], [38], [125], [148].  
2.4 Adipose Tissue 
Adipose tissue, derived from pre-adipocytes, is a loose connective tissue found throughout the 
body. Its primary role is to act as a regulator of energy metabolism by storing excess energy 
taken in through diet [149]. Energy is taken up by the adipose tissue in the form of free fatty 
acids (FFAs) with the aid of lipoprotein lipase (LPL). The FFAs are then converted to 
triglycerides (TG) within the adipocytes. When the body is in a state of caloric deficit, the stores 
of TG are liberated from the adipocytes by lipase in the form of FFAs and glycerol, to be 
oxidized and used as energy throughout the body [150], [151]. Due to its role in energy 
metabolism, adipose tissue is one of the few organs within the body that is capable of large 
changes in mass during adulthood. The typical adult female is approximately 30% fat by body 
weight, whereas males are typically around 20% body fat [151]. 
Adipose tissue is also an important regulator of body temperature and acts to insulate the body 
and protect internal organs against mechanical damage [100]. Adipose tissue immediately 
surrounding the internal organs is termed ‘visceral fat’, while the anatomical depot underlying 
the dermis is considered ‘subcutaneous fat’ [152]. Due to the fact that adipose tissue is highly 
vascularized and innervated, it is no surprise that it is also a highly active endocrine organ [153]. 
Adipose tissue is capable of not only responding to afferent signals, but secreting factors of its 
own. Adipokines such as leptin and adiponectin are secreted by this endocrine organ [149], 
[153]. Leptin, more commonly known as the ‘satiety signal’, is known for regulating energy 
metabolism by regulating appetite [153], [154]. Leptin is released by visceral adipose tissue to 
signal the body to stop eating. When energy stores are low, leptin levels are decreased and this 
allows the body to feel hunger, acting as a negative feedback loop to regulate food intake [154]. 
Adiponectin aids in the breakdown of FFAs and assists in controlling blood glucose levels [149], 
[100], [155]. Metabolism of sex steroids and glucocorticoids also takes place within adipose 
tissue, suggesting that hormones play an important role in the different distributions of body fat 
that are present between males and females [149], [153]. 
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The type of adipose tissue found within adults is termed white adipose tissue. There is another 
form of adipose tissue found in infants and young children termed brown adipose tissue [156]. 
The primary role of brown adipose tissue is to regulate body temperature though heat production 
[156]. Brown fat uses a large amount of energy to produce heat in a method called non-shivering 
thermogenesis [154]. As people age, brown adipose tissue is replaced by white adipose tissue as 
other processes are able to take over temperature regulation [157].  Adipose tissue acquired for 
the purposes of cell isolations or decellularization procedures is white adipose tissue.  
2.4.1 Adipose ECM Composition  
As previously mentioned, the ECM is a complex mixture of proteins, proteoglycans, and 
glycoproteins secreted by cells. Adipose tissue ECM also contains a variety of adhesion proteins, 
growth factors and cytokines [100]. Integrins connect the ECM to the intracellular cytoskeleton, 
which can lead to signaling cascades in response to mechanical stimulation that can spread to 
neighboring cells [86]. Cellular cohesion is important in adipose tissue as it is a very dynamic 
environment. MMPs enzymatically digest structural components of the ECM to allow for 
cellular migration and release of ECM-bound molecules [91].  
Collagen makes up a large component of adipose tissue ECM. Adipocytes are surrounded by a 
collagen IV-rich matrix that protects the lipid-filled cells from rupturing [101]. The ECM of 
adipose tissue is primarily comprised of collagens I, II, III, IV, XII XIV, XV, and XVII, as well 
as laminin, fibronectin, elastin, GAGs, and various proteoglycans. Among these, collagen I and 
IV are the most abundant [86]. Type I collagen is a fibril-forming collagen with a right-handed 
triple helix structure, with two of the α-chains being identical [105]. This is the most prevalent 
type of collagen in adipose tissue. As previously discussed, collagen IV is the most abundant 
structural component of basal lamina ECM. Collagen IV is a network-type collagen that does not 
form fibres, but rather it is arranged into a highly crosslinked mesh [105], [104], which surrounds 
the adipocytes, and contains laminins, nidogens, heparin sulphates, and other basement 
membrane components [101], [99].  
Adipose tissue ECM also includes bioactive components such as GAGs and proteoglycans, as 
well as growth factors. GAGs help to keep the tissue hydrated and are often bound to proteins to 
form proteoglycans. The most common proteoglycans in adipose tissue are small leucine-rich 
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proteoglycans called decorin and biglycan [158], [159]. These proteoglycans can have major 
effects on lipid transport/absorption, along with other cellular behaviors [160], [161].  VEGFs 
are pro-angiogenic proteins that are present within the ECM, which are secreted by ASCs and 
associated with regulating the bioactivity of adipose tissue through signaling for the formation of 
new blood vessels [162].  
2.4.2 Decellularized Adipose Tissue Scaffolds 
Decellularized adipose tissue (DAT) has many applications as a scaffolding material. Building 
on the framework of Flynn et al., recent studies have demonstrated the widespread applications 
of DAT scaffolds for cell-based therapies [131]. Microcarriers, porous bead foams, foams, and 
powders have demonstrated that DAT is adipo-inductive, suggesting that adipogenesis can be 
induced by the matrix alone [125], [163]. DAT scaffolds have also shown promise with regards 
to promoting angiogenesis in vivo [53].  
Generally, adipose decellularization approaches require multiple freeze/thaw cycles in hypotonic 
buffers to aid in initial cell lysis, and open up membranes for additional exposure to elements of 
decellularization [82], [136], [164]. Enzymatic digestion is also common with the use of 
trypsin/EDTA, to disrupt cell-cell adhesion [82]. Subsequent enzymatic treatments with endo- 
and exo-nucleases such as DNase and RNase to remove any remaining nuclear material that may 
cause an immunogenic response are common [18]. The use of detergents to ensure sufficient 
removal of cellular material from the ECM and disrupt interactions between lipids and proteins is 
also a common procedure [82], [131]. Several methods for decellularizing adipose tissue involve 
the use of collagenase to break down the tissue, mechanical massaging, and rinses in various 
concentrations of SDS, sodium deoxycholate, or Triton X-100, and isopropanol, followed by 
lyophilization [165].  However, there is growing evidence to support the notion that detergents 
degrade the ECM and if residual detergent remains in the ECM, it can by cytotoxic to cells 
[166], [167]. Flynn et al. recognized the importance of developing a uniquely detergent free 
decellularization protocol and pioneered new methods to better preserve the native ECM [9].  
The Flynn method of decellularization is a 5-day protocol that involves a combination of 
freeze/thaw cycles in hypotonic solutions followed by high salt rinses, enzymatic digestion in 
trypsin/EDTA and endonucleases, mechanical digestion, and washes in isopropanol [131]. An 
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optimized 3-day protocol was also developed that removes the requirement of enzymatic 
digestion with DNase and RNase, but continues the use of trypsin/EDTA. Studies to characterize 
the resulting ECM have been accomplished, demonstrating that collagen I and IV, laminin, 
fibronectin, VEGF-A and adiponectin are retained in the DAT [168].   
In the intact form, DAT is an amorphous white substance that when lyophilized, has many 
applications. DAT can be used in the intact form, however, the ability to use it as a tunable ECM 
source to fabricate varied scaffold designs shows promise for widespread applications in tissue 
engineering [46], [131], [165]. Additionally, not many studies have investigated the use of 
tissue-specific ECM on adipogenic differentiation, highlighting the need for further research in 
this area. 
2.5 Cartilage Tissue 
Cartilage tissue can be classified into three categories: hyaline (articular) cartilage, elastic 
cartilage, and fibrocartilage [169]. Hyaline or articular cartilage is typically found on joint 
surfaces, in the bridge of the nose, and trachea. It contains a white, shiny elastic matrix of 
various proteoglycans such as aggrecan, chondroitin sulphate, keratin sulphate, biglycan, 
fibromodulin, and decorin [170], [171]. Elastic cartilage is found in parts of the larynx but is 
most commonly associated with the outer ear. It is more yellow in color and is contained within a 
perichondrium. The perichondrium surrounds the surface of most cartilage within the body and is 
comprised of a dense, irregular connective tissue [112], [154], [172]. Fibrocartilage is found in 
the intervertebral discs, pubic symphasis, and the menisci of the knee [173]. The exception to 
this is in the case of injury; the body may remodel damaged articular cartilage into fibrocartilage 
during scar formation [174]. Fibrocartilage is the toughest of the three cartilage types as it 
consists of dense bundles of collagen fibres and chondrocytes. This tissue does not contain a 
perichondrium [175].  
It is generally accepted that cartilage has a limited capacity for self-repair due to minimal 
vascularity of cartilage tissues and low cell numbers [164]. In general, cartilage is considered to 
be both avascular and aneural, except for the small blood vessels and nerves found within the 
perichondrium [173], [175], [176]. This greatly increases the need for tissue regeneration 
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strategies, particularly for articular cartilages found within joints, and the fibrous cartilage of the 
meniscus. These are the two areas that see the most common tissue damage [177].  
Articular cartilage functions to protect the surface of the joints and prevent high friction on the 
ends of endochondral bone and is the most abundant of the three types of cartilage found within 
the body [123]. Type IV collagen can be found within the pericellular region of cartilage, a 
distinct region just outside the cell membrane [92]. Cartilage is a dense matrix of collagen II, 
aggrecan, and GAGs that are produced by the resident chondrocytes, as outlined in detail in the 
next section. These chondrocytes are typically found within spaces called lacunae [172].  
Chondrocytes have a rounded or ovoid morphology and are known for secreting large amounts 
of matrix, primarily collagen II and various GAGs [178], [179]. The large water and collagen 
contents combined with minimal vascularization give the ‘white’ appearance that is often 
associated with cartilage [112]. Fibronectin has also been found in the ECM of meniscal 
cartilage [175]. Healthy articular cartilage is approximately 70-85% water, allowing for 
appropriate joint lubrication at articular surfaces [173], [175]. Cartilage remodeling is a slow 
process that involves careful balance of MMPs and tissue inhibitors of metalloproteinases 
(TIMPs) [176]. Cartilage is a very dense tissue, with chondrocytes comprising only 5-10% of the 
tissue [170], [180]. For this reason, harvesting cells from cartilage yields low cell numbers and 
raises the need for cell-based therapies to aid in tissue regeneration [176]. 
2.5.1 Cartilage ECM Composition 
Within cartilage, resident chondrocytes secrete the structural and bioactive molecules that 
comprise the ECM. As discussed above, 70-85% of whole cartilage tissue is comprised of water 
[123], the majority of which resides within the ECM [173]. Collagens, proteoglycans, 
glycoproteins, and small traces of elastin comprise 20-30% of the wet weight of articular 
cartilage. Of that 20-30% wet weight, approximately 16% is comprised of collagens [112]. 
Elastic cartilage is very similar in composition to articular cartilage, except that it contains an 
extensive network of elastic fibres [111], [115]. Various assays such as the dimethylmethylene 
blue (DMMB) assay or hydroxyproline assay are typically used to estimate GAG or collagen 
content respectively [181]–[184].  
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Collagen types I – VI, IX, X, and XI have been reported within the ECM of various cartilage 
tissues, with collagen type II being the most abundant [173], [185]. Cross-links form between 
collagen type II molecules to create collagen fibres. The intramolecular bonds formed create a 
strong collagen lattice that gives rise to the tensile properties of cartilage tissue [186]. Within the 
cartilage ECM, the high molecular weight proteoglycan aggrecan, which contains chondroitin 4-
sulphate, chondroitin 6-sulphate, and keratin sulphate, interacts with hyaluronic acid to form 
large aggregates that impart resistance to compressive loads [111], [173]. In addition, 
chondronectin is an important glycoprotein, as it binds collagens, GAGs, and integrins in order 
to mediate chondrocyte adherence in the ECM [111]. Cartilage oligomatrix protein (COMP) is 
commonly used as a marker of cartilage turnover and encodes a non-collagenous protein that 
aids in cell binding and attachment [187]. 
Collagens within the ECM have unique fibre orientations that directly contribute to 
biomechanical functions and strength. When imaged microscopically, sheets of longitudinally 
arranged fibres can be seen in fibrocartilage [188]. The meniscus of the knee has three distinct 
layers, each arranged in different directions, which resist tensile stresses placed on the tissue 
[113], [175]. Fibrous and hyaline cartilage both have superficial and deep zones. Hyaline 
cartilage has an additional intermediate zone and a calcified zone [170], [189], [190]. The 
superficial zone protects deeper layers from biomechanical stress and the collagen fibres are 
tightly packed in parallel to the articular surface [170]. The intermediate zone is a transitional 
zone that contains slightly thicker collagen fibres and more spherical cells. The deep zone, 
representing 30% by volume, provides the greatest resistance to compressive forces and contains 
collagen fibres that are arranged perpendicular to the articular surface [113], [191]. Within the 
deep zone, chondrocytes are typically arranged in columns and show markers of ossification and 
hypertrophy as the cartilage is anchored to the bone by collagen fibrils [170].  
2.5.2 Decellularized Cartilage Tissue (DCT) Scaffolds 
Decellularized cartilage has shown promise in tissue engineering of articular cartilage, menisci, 
tracheal cartilage, and temporomandibular joint disc [130], [192]–[195]. Like adipose tissue, 
common cartilage decellularization protocols involve the use of multiple freeze/thaw cycles, 
rinses in hypotonic buffers, enzymatic digestion, and washes in detergents [21], [22], [143], 
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[147]. Commonly used detergents include Triton X-100, SDS, sodium deoxycholate, and TBP. 
Although cartilage tissue contains fewer cells than adipose tissue, the dense nature of the tissue 
poses a challenge when attempting to extract cellular material. Rinses must occur at higher 
agitation to perform proper extraction. Mechanical disruption of the tissue by increasing surface 
area is speculated to assist in the decellularization process [1], [127]. There is no standard 
decellularization method for cartilage tissue, highlighting the need for studies in this area. After 
decellularization, the resulting ECM can be used to create 3-D scaffolds or cell constructs. 
To date, approaches have used the intact scaffold such as an ECM plug to promote 
chondrogenesis [143], [164]. DCT has also been examined in its powder form as a potentially 
injectable ECM source [1]. However, as discussed previously, cartilage is a very dense tissue and 
the nature of the ECM makes cell infiltration into decellularized cartilage ECM quite difficult. 
Various studies have suggested that the thickness of DCT plays an important role in cell 
infiltration, and is therefore a key consideration in cartilage tissue engineering [196]. Gong et al. 
attempted to combat this by developing a ‘sandwich model’ where twenty 10 µm- or 30 µm-
thick articular cartilage sheets were stacked with a 5 L suspension containing 100 × 
106 cells/mL between each sheet and cultured for 16 weeks [130]. The sheets containing 10 µm 
slices demonstrated greater collagen staining when compared to the 30 µm sheets. In general, 
poor cellular infiltration in cartilage tissue engineering may be combated by using thin sections 
of DCT or DCT particles [197], [183], [56]. Some studies have also tried to incorporate in vitro 
cell-derived DCT with a polymer such as collagen or alginate as a template [198], [199]. In a 
study by Sutherland et al. both cell-derived DCT and devitalized DCT particles demonstrated 
upregulation of collagen II and down-regulation of collagen I, X, and RUNX2 [22]. Cell-derived 
DCT was composed of cell-secreted matrix from in vitro cultures, whereas devitalized particles 
were derived from native tissue. While several different methods of incorporating various types 
of DCT into 3-D scaffolds have been explored, the best method for fabricating cell-ECM 
constructs for chondrogenesis has yet to be determined [8], [20], [143], [147], [183], [200]. 
Challenges of using intact DCT scaffolds remain that rigorous decellularization protocols may 
lead to greater destruction of the ECM. Additionally, thinner DCT scaffolds may decrease the 
biomechanical resilience of the native tissue and may have some unknown effects on 
chondrogenesis [200]. There is a great need for studies in the area of cartilage tissue engineering, 
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as regeneration remains challenging due to the avascular and aneural nature of the tissue. If 
standard methods of cartilage decellularization could be established that minimize damage to the 
ECM, DCT scaffolds could represent a promising new cell instructive bioscaffolding platform 
for tissue regeneration and/or cell delivery.  
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Chapter 3  
3 Methods 
All chemical reagents for this project were purchased from Sigma-Aldrich Canada Ltd. 
(Oakville, Ontario) unless otherwise indicated. 
3.1 Objective 1: Tissue Procurement and Decellularization 
3.1.1 Adipose Tissue Procurement and Decellularization  
Subcutaneous human adipose tissue was obtained with informed consent from patients 
undergoing routine breast reduction surgeries at the University Hospital in London, Ontario, with 
Research Ethics Board approval from Western University (HREB# 105426). The tissues were 
transported to the lab on ice in 10 mM Tris buffer (pH 8.0) within 2 hours of excision. 
Cauterized tissue was removed and the remaining adipose tissue was stored in 10 mM Tris buffer 
at -80°C. Adipose tissue decellularization was performed using established detergent-free 
methods [9]. A working volume of 100 mL was used for all processing steps and all 
decellularization solutions were supplemented with 1% (v/v) antibiotic-antimycotic (ABAM) 
(Gibco®, Invitrogen, Burlington, Ontario) and 0.27 mM phenylmethylsulfonyl fluoride (PMSF).  
In brief, the adipose tissue was subjected to three freeze-thaw cycles in “solution A” comprised 
of 10 mM Tris buffer containing 5 mM ethylenediaminetetraacetic acid (EDTA) at pH 8.0. After 
the final thawing step, the samples were incubated for 2 hours in fresh solution A under agitation 
at 120 RPM and 37°C, and then centrifuged at 1500 x g for 30 minutes. The adipose tissue was 
incubated again in solution A for 2 hours, and then transferred into 0.25% trypsin/EDTA 
(Gibco®, Invitrogen, Burlington, Ontario) and incubated overnight under agitation at 120 RPM 
and 37°C (minimum 8 hours). The following morning, the tissue was incubated in 100% 
isopropanol for 3 hours under agitation at 120 RPM and 37°C to extract lipids. Subsequently, the 
tissue was compressed with stainless steel filters to enhance lipid separation, placed in 50 mL 
conical tubes containing fresh 100% isopropanol, and centrifuged at 1500 x g for 30 minutes. 
The isopropanol extraction, mechanical compression, and centrifugation steps were repeated 
once before the tissue was incubated in isopropanol under agitation at 120 RPM and 37°C 
overnight. The following morning, the sample was manually compressed to remove residual 
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lipid, and incubated in isopropanol for an additional 4 hours under agitation at 37°C. The 
decellularized adipose tissue (DAT) was then mechanically compressed once more and 
rehydrated in Sorenson’s phosphate buffer (SPB) rinse solution, containing 8 g/L NaCl, 200 
mg/L KCl, 1 g/L Na2HPO4, and 200 mg/L KH2PO4 (pH 8.0), through three 30 minute rinses at 
37°C under agitation at 120 RPM. The DAT was then rinsed several times in deionized water 
(dH2O) prepared with the Barnstead GenPure xCAD Plus system (Thermo Fisher Scientific, 
Ottawa, ON, Canada) prior to being lyophilized, as described in section 3.2.1. 
3.1.2 Cartilage Tissue Procurement and Decellularization 
Porcine ears were obtained from Mount Brydges Abattoir in Mount Brydges, Ontario for use as 
an auricular cartilage source. The tissues were transported to the lab on ice within one hour of 
sacrifice. To enhance the cartilage surface area in contact with the decellularization reagents, the 
dermis was removed with a scalpel and the cartilage was sectioned into small discs using a 5 mm 
biopsy punch. The tissue samples were placed in phosphate buffered saline (PBS) and rinsed 
three times under agitation at 200 RPM for 10 minutes at room temperature.  
Adapting protocols from Xu et al. [136], two decellularization protocols were initially tested. A 
solution volume of 50 mL was used and all solutions were supplemented with 1% (v/v) ABAM 
and 0.27 mM PMSF. The two protocols were very similar, differing only in the buffer used 
during the incubation with deoxyribonuclease (DNase) and ribonuclease (RNase).   
First, the tissue samples were subjected to three freeze-thaw cycles in 10 mM tris buffer (pH 
8.0). Next, the samples were incubated in a high salt tris buffer containing 1.5 M KCl and 2% 
Triton X-100 at 37°C and 200 RPM for 48 hours, with solution changes twice per day. 
Subsequently, the tissue was rinsed three times in PBS for 30 minutes each at 37°C under 
agitation at 200 RPM. The cartilage was then rinsed in SPB rinse three times for 30 minutes 
under agitation at 200 RPM and 37°C. To test two different enzymatic digestion conditions, 
cartilage samples were then transferred into one of the following buffers supplemented with 12.5 
mg RNase Type III A (from bovine pancreas) and 15,000 U DNase Type II (from bovine 
pancreas) for 72 hours under agitation at 200 RPM and 37°C:  
Protocol 1A: a 10:1 ratio of PBS to 0.5% trypsin/EDTA 
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Protocol 1B: a 10:1 ratio of 50 mM tris buffer to 0.5% trypsin/EDTA  
All solutions were replaced twice daily. The enzymatic digestion stage was followed by 
incubation in PBS at 37°C and 200 RPM for 24 hours, with the solutions replaced once. The 
samples were then incubated at 37°C and 200 RPM in 50 mM Tris buffer (pH 9.0) for 48 hours 
and finally, the decellularized cartilage was rinsed several times in PBS and dH2O. The samples 
were then prepared for histological analysis, as described in section 3.1.3. 
Based on the initial histological results, three different decellularization protocols were 
subsequently tested, based on the work of Woods and Grazter [201]. For all three protocols, the 
cartilage discs were first subjected to three freeze-thaw cycles in 10 mM tris buffer containing 5 
mM EDTA (pH 8.0). The samples were then incubated in a high salt Tris buffer containing 1.5 
M KCl and 1% Triton X-100 for 48 hours at 37°C and 200 RPM, with solution changes twice 
per day. The samples were then rinsed three times in SPB rinse for 30 minutes under agitation at 
200 RPM and 37˚C. Next, the samples were enzymatically digested in Sorenson’s phosphate 
buffer digest (SPB Digest) (55 mM Na2HPO4, 17 mM KH2PO4, 4.9 mM MgSO4•7H2O) 
supplemented with 12.5 mg RNase Type III A (from bovine pancreas) and 15,000 U DNase 
Type II (from bovine pancreas) for 5 hours under agitation at 200 RPM and 37 ˚C. Following 
digestion, the tissues were then processed using one of three conditions to extract residual 
cellular debris under agitation at 200 RPM and 37 ˚C for 48 hours: 
Protocol 2A: 1% tributyl phosphate (TBP) in 50 mM tris buffer 
Protocol 2B: 2% Triton X-100 in 50 mM tris buffer 
Protocol 2C: 1% sodium deoxycholate (SDC) in 50 mM tris buffer 
The decellularized cartilage samples were then rinsed three times in PBS and three times in 
dH2O for 30 minutes each, and incubated in 50 mM Tris buffer (pH 9.0) under agitation at 200 
RPM and 37 ˚C for 48 hours. Finally, the decellularized cartilage was rinsed several times in 
PBS and dH2O and prepared for histological analysis as described in Section 3.1.3.  
Based on the results of the second decellularization trial, a slightly modified decellularization 
method was tested in which the concentration of Triton X-100 in the initial detergent extraction 
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phase was increased from 1% to 2%. This final cartilage decellularization protocol (Protocol 2D) 
is summarized in Table 3.1, and was used as the approach for all subsequent experiments. 
Table 3.1: Final Cartilage Decellularization Protocol 
Day 1 
 3 x 15 minute rinse in PBS  
 Three freeze/thaw cycles in 10 mM Tris buffer containing 5 mM 
EDTA (pH 8.0). Replace solutions after each thaw. 
 Incubate cartilage in 10 mM Tris buffer containing 5 mM EDTA for 
24 hours, changing solutions twice  
Days 2-3 
 Incubate in high salt Tris buffer containing 1.5 M KCl + 2% Triton 
X-100 for 48 hours 
 Change solutions twice per day 
Days 4 - 5 
 3 x 30 minutes in SPB rinse  
 Incubate in SPB digest + RNase + DNase for 5 hours  
 Incubate in 50 mM Tris buffer + 1% TBP for 48 hours  
 Replace solutions twice per day 
Days 6 - 7 
 3 x 30 minutes in dH20  
 3 x 30 minutes in PBS  
 48 hour rinse in 50 mM Tris buffer (pH 9.0)  
 Replace solutions twice per day  
Day 8 
 3 x 30 minutes in PBS  
 3 x 30 minute rinse in 70% ethanol at room temperature under 
agitation 
 3 x 15 minute rinse in sterile PBS at room temperature under 
agitation 
 Store in sterile PBS supplemented with ABAM and PMSF  
*Note: All processing steps carried out under agitation at 200 RPM and 37˚C, and all solutions 
supplemented with 1% ABAM and 0.27 mM PMSF. 
3.1.3 Histological Analysis 
Processed cartilage samples from the different decellularization trials, along with native porcine 
auricular cartilage control samples, were fixed overnight in 4% paraformaldehyde (PFA). The 
samples were then rinsed in dH2O, placed in 70% ethanol, and brought to Robarts Molecular 
Pathology Laboratory in London, Ontario, for processing. The samples were then embedded in 
paraffin and sectioned (7 m sections) using a Leica RM2235 microtome (Leica Biosystems, 
Concord, ON, Canada). The sections were deparaffinzed by incubating the slides in xylene for 
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10 minutes (2X) and then rehydrated in an ethanol series (100% (2X), 95%, 90%, 80% 70% 
EtOH in dH2O for 5 minutes each), followed by dH2O. Masson’s trichrome staining, 0.1 % 
safranin O/fast green staining, and DAPI staining using fluoroshield mounting medium 
(ab104139, Abcam) were performed to characterize the tissues.  
3.2 Objective 2: Milling and Characterization of ECM Particles 
Breast adipose tissue from three human donors (N=3) was decellularized and pooled to generate 
a DAT stock that was used for all subsequent studies. Similarly, porcine auricular cartilage from 
three pigs (N=3) was decellularized and combined to yield a DCT stock. This approach was 
undertaken to eliminate batch-to-batch variability in the ECM sources when assessing the effects 
of the decellularized ECM on ASC differentiation.  
3.2.1 Lyophilization and Cryogenic Milling  
The DAT and DCT samples were rinsed in dH2O and frozen at -80°C for 8 hours in 50 mL 
conical tubes covered in perforated aluminum foil. The tubes were then transferred on dry ice to 
the Labconco Freezone 4.5 lyophilizer (Labconco, Kansas City, MO, United States) and dried 
for 48 hours. After lyophilization, the pooled DAT or DCT was finely minced with scissors, and 
transferred into a Retsch 25 mL cryo-milling grinding jar. Two thirds of the milling jar was filled 
with minced ECM, and two 10 mm stainless steel milling balls were placed in the milling jar. 
The cap was tightened, and the jar was immersed in liquid nitrogen for 3 minutes. The tissues 
were then milled for 3 minutes at a frequency of 30 Hz using the Retsch Mixer Mill MM 400 
milling system. The cycle of immersion in liquid nitrogen and milling were repeated at least once 
to obtain a fine powder; during humid weather, additional cycles were required. The particles 
were then separated based on size using stainless steel sieves (W.S. Tyler, St. Catharines, ON, 
Canada) of decreasing mesh sizes in the following order: 300 μm, 250 μm, 125 μm, and 45 μm. 
3.2.2 Particle Size Analysis 
Particle size analysis was completed for both the DAT and DCT particles collected between the 
45 µm and 125 µm sieves using a Malvern Mastersizer 2000 (Malvern Instruments Ltd., 
Worcestershire, United Kingdom). Approximately 1 g of dehydrated ECM particles was placed 
in 500 mL of dH2O with 5 drops of Triton X-100 detergent to disrupt surface tension and reduce 
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aggregation of the ECM particles. The samples were then analyzed following the manufacturer’s 
instructions. For each pooled ECM source, 3 technical replicates (n=3) were analyzed. The data 
was plotted as the mean ± standard deviation (SD). A Kolmogorov–Smirnov test with p < 0.05 
was performed using GraphPad Prism 6 (GraphPad Software, San Diego, CA) to assess whether 
the particle size distributions for the DAT and DCT particles were statistically equivalent. 
3.2.3 Scanning Electron Microscopy 
Scanning election microscopy (SEM) was performed on both the DAT and DCT particles 
collected between the 45 µm and 125 µm sieves to visualize the ECM ultrastructure after milling 
and sieving. Lyophilized, cryo-milled DAT and DCT particles were mounted onto stubs with 
conductive carbon tape and coated with 10 nm of osmium before visualization with a LEO 1530 
scanning electron microscope. The samples were imaged at 700 and 1000 times magnification 
with an accelerating voltage of 1.00 kV and a working distance of 6 mm.  
3.3 Objective 3: In vitro cell culture studies 
3.3.1 ASC Isolation  
Subcutaneous human adipose tissue was obtained with informed consent from patients 
undergoing routine breast reduction surgeries at the University Hospital in London, Ontario 
(HREB# 105426).  Adipose tissue samples were transferred to the lab on ice in PBS 
supplemented with 20 mg/mL bovine serum albumin (BSA), and processed within 2 hours of 
tissue extraction. Adipose-derived stem/stromal cell (ASC) isolation was performed using 
established protocols [202]. Cauterized tissue was removed and the adipose tissue was finely 
minced using scissors. The minced adipose was then digested for 45 minutes with 2 mg/mL 
collagenase type I (Worthington Biochemical Corporation, Lakewood, NJ, United States) in 
sterile Kreb’s Ringer bicarbonate buffer supplemented with 3 mM glucose, 25 mM HEPES and 
20 mg/mL BSA at 37°C under agitation at 100 RPM. The digested sample was filtered through a 
250 µm stainless steel filter into a 50 mL conical tube, and the mature adipocyte layer was 
removed by aspiration following gravity separation. An equal volume of complete medium 
comprised of DMEM/Ham’s F12 supplemented with 10% fetal bovine serum (FBS) (Gibco®, 
Invitrogen, Burlington, Ontario) and 100 U/mL of penicillin with 0.1 mg/mL streptomycin (pen-
strep) (Gibco®, Invitrogen, Burlington, Ontario) was added to the sample, which was then 
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centrifuged at 1200 x g for 5 minutes. The supernatant was discarded and the pellet was 
resuspended in an erythrocyte lysing buffer (0.154 M ammonium chloride, 10 mM potassium 
bicarbonate, and 0.1 M EDTA in sterile dH2O) for 10 minutes at room temperature under gentle 
agitation. The sample was then centrifuged for 5 minutes at 1200 x g, resuspended in complete 
media, filtered through a 100 µm filter, and re-centrifuged. The cell pellet was then resuspended 
in complete medium and plated on T-75 culture flasks at a density of 30,000 cells/cm2. The 
media was exchanged every 2-3 days. When the cells were at approximately 80% confluence, 
they were passaged 1:4 using 0.25% tryspin-EDTA and re-plated in new T-75 culture flasks.  
3.3.2 ASC Immunophenotype  
The immunophenotype of passage 2 ASCs was analyzed using a Guava® 8HT flow cytometer 
(EMD Millipore Corporation, Darmstadt, Germany) following published protocols [152]. Single 
marker staining was performed (n=3 technical replicates, N=3 cell donors) with monoclonal, 
fluorochrome-conjugated antibodies (eBioscience, San Diego, CA). The positive markers 
assessed were CD90, CD44, CD29, CD73, and CD105. CD34 was also analyzed, which is 
reported to be expressed in early passage ASCs, but declines with passaging [54]. CD146 was 
also analyzed as a marker of pericyte-like cells [54]. The negative markers assessed were CD31 
(endothelial) and CD45 (hematopoietic). All trials included controls with unlabeled cells.  
3.3.3 Validation of Cell Aggregate Culture Methods 
The initial method used to fabricate 3-D cell aggregates involved transferring 1 mL of ASC 
suspension at a concentration of 1x106 cells/mL into an uncapped 1.5 mL microcentrifuge tube 
positioned inside of a 15 mL vented-cap conical tube, which was then centrifuged at 300 x g for 
10 minutes and then maintained in culture for 48 hours [38]. Based on histological analysis using 
Masson’s trichrome staining (Figure 3.1), this approach generated non-spherical cell aggregates 
that were easily disrupted. As such, an alternate approach was adopted based on the methods of 
Gimble et al. [10]. In this strategy, 1 mL of ASC suspension at a lower concentration of 2.5x105 
cells/mL was transferred directly into a 15 mL vented-cap conical tube, centrifuged at 300 x g 
for 5 minutes and cultured for 48 hours to yield robust spherical cell aggregates (Figure 3.1).  
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Figure 3.1 Methods used for generating cell aggregates. (a) 1 million cells cultured in 1.5 mL 
microcentrifuge tubes (b) 2.5x105 cells cultured in 15 mL conicals. (scale bars=100 m). 
3.3.4 Validation of Chondrogenic Medium Formulation 
A pilot study was performed on ASC aggregates generated using the refined approach described 
in the previous section to verify that the cells cultured in this configuration could be successfully 
induced to express chondrogenic markers when maintained in chondrogenic differentiation 
medium for 28 days. The chondrogenic medium formulation was selected based on the work of 
Neupane et al. [203], [12] and was comprised of DMEM:Ham’s F12 supplemented with 10% 
FBS, 1% pen-strep, 50 μM ascorbate-2-phosphate, 6.25 μg/mL insulin, 100 nM dexamethasone, 
and 10 ng/mL TGF-β1 (R&D Systems, CAT#: 100-B-001). For comparison, a second medium 
formulation reported by Guilak et al. [71] was also tested, which was comprised of 
DMEM:Ham’s F12 supplemented with 10% FBS, 1% pen-strep, 50 μM ascorbate-2-phosphate, 
1% ITS+premix supplement (Collaborative Research, CAT#: 40352), 100 nM dexamethasone, 
and 10 ng/mL TGF-β3 (R&D Systems, CAT#: 243-B3-010). Non-induced control aggregates 
were maintained in complete medium for the duration of the 28-day culture period. To assess 
chondrogenic differentiation, cell aggregate samples (n=3) were embedded in OCT and cryo-
sectioned for immunohistochemical (IHC) analysis of collagen II and collagen I expression, 
described in detail below. Additional samples (n=3) were fixed in 4% PFA, paraffin-embedded 
and sectioned for histological analysis of GAG accumulation by safranin O staining. Native 
porcine cartilage was included as a positive control for the IHC and histological analyses.  
For IHC analysis, samples were cryo-sectioned (7 µm) with a Leica RM2235 microtome (Leica 
Biosystems, Concord, ON, Canada) and collected onto Superfrost® Plus microscope slides 
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(Thermo Fisher Scientific, Ottawa, ON, Canada). The sections were warmed at 60˚C for 40 
minutes before being transferred to the -20˚C freezer for storage. Immediately prior to staining, 
the slides were warmed to room temperature and subjected to antigen retrieval using DAKO 
citrate buffer (DAKO, Mississauga, ON, Canada) at 95˚C for 30 minutes, then allowed to cool to 
room temperature. The slides were subsequently rinsed in Tris buffered saline (TBS) containing 
0.025% Triton X-100, and blocked with 10% goat serum for 1 hour to control for non-specific 
binding of the primary antibody. The samples were then incubated in rabbit anti-collagen II 
antibody (ab34712, Abcam) diluted to 1:500 in TBS supplemented with 1% BSA solution 
overnight at 4˚C, or mouse anti-collagen I antibody (ab90395, Abcam) diluted to 1:500 in TBS 
supplemented with 1% BSA for 1 hour at room temperature. Following this, the sections were 
rinsed with TBS and incubated in Dylight® 650 goat anti-mouse IgG H&L (ab96882, Abcam) 
for collagen I and Dylight® 650 goat anti-rabbit IgG H&L (ab96902, Abcam) for collagen II, 
each diluted to 1:500 in TBS supplemented with 1% BSA for one hour at room temperature. The 
sections were rinsed, and mounted with mounting medium containing DAPI before imaging with 
an Evos FL cell imaging system (Thermo Fisher Scientific, Ottawa, ON, Canada).  
To assess GAG accumulation within the pellets by safranin O staining, the paraffin-embedded 
and sectioned samples were collected onto Superfrost® Plus microscope slides and 
deparaffinized with xylene, followed by rehydration in an ethanol series, and finally to dH20. 
The sections were then stained with 0.1% safranin O for 5 minutes before being dehydrated with 
95% ethanol for 2 minutes, 100% ethanol for 2 minutes, and cleared in xylene. The slides were 
mounted using Permount™ mounting medium (Fisher Scientific, Ottawa, ON, Canada) for 
imaging with an Evos XL Core imaging system (Fisher Scientific, Ottawa, ON, Canada).  
3.3.5 ASC + ECM Aggregate Formation 
Using the milled DAT or DCT particles collected between the 45 µm and 125 µm sieves, 
ASC+ECM aggregates comprised of 2.5x105 ASCs and 0.075 mg ECM per aggregate were 
fabricated. To fabricate the aggregates, milled DAT or DCT was placed under UV light for 30 
minutes before being weighed using a Sartorius CPA225D scale (Sartorius, Bradford, MA, 
United States). The milled ECM particles were rehydrated in complete medium at a 
concentration of 0.075 mg/mL. 100 µL of the medium containing ECM was transferred into a 15 
mL vented-cap conical tube containing 2.5x105 passage 2 ASCs suspended in 900 µL of 
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complete medium.  The samples were centrifuged at 300 x g for 5 minutes and cultured for 48 
hours. Masson’s trichrome staining was performed to confirm that the ECM particles were 
successfully integrated into the cell aggregates. To further verify ECM incorporation, a pilot 
study was performed in which the DAT and DCT particles were pre-labeled with an amine-
reactive Alexa fluor 350 succinimidyl ester (Molecular Probes, Burlington, Ontario) prior to 
aggregate formation using published methods [127]. At 48 hours, the aggregates were cryo-
sectioned and visualized by fluorescence microscopy, with SYTOX orange nuclear staining. 
3.3.6 In vitro Culture Study Design  
Detailed in vitro cell culture studies were conducted to explore the effects of the tissue-specific 
ECM particles on mediating the lineage-specific differentiation of the ASCs in the 3-D 
ASC+ECM aggregate cultures. Table 3.2 summarizes the experimental groups and culture 
conditions investigated for the adipogenic and chondrogenic lineages. All experiments were 
repeated with passage 2 ASCs sourced from 3 different donors (N=3), using the pooled DAT and 
DCT stocks that were previously characterized. 
Table 3.2: Summary of Differentiation Studies  (N=3 cell donors for each lineage).  
Culture 
Groups 
Adipogenic Differentiation 
Time point = 14 days 
Chondrogenic Differentiation 
Time point = 28 days 
DAT+ASCs Complete Medium Complete Medium 
Adipogenic Medium Chondrogenic Medium 
DCT+ASCs Complete Medium Complete Medium 
Adipogenic Medium Chondrogenic Medium 
ASCs Only 
(Control) 
Complete Medium Complete Medium 
Adipogenic Medium Chondrogenic Medium 
 
For the cell culture studies, ECM+ASC and ASC-alone aggregate samples were cultured for 14 
or 28 days in either adipogenic or chondrogenic differentiation medium using the formulations 
summarized in Table 3.3. To assess whether the ECM particles or 3-D culture configuration had 
any inductive effects on ASC differentiation, non-induced control samples maintained in 
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complete medium were included for all assays, with the exception of the quantitative reverse-
transcriptase-polymerase chain reaction (RT-qPCR) studies. 
 
Table 3.3 Differentiation Medium Formulations  *= only for first 72 hours 
Complete Media Adipogenic Medium [9] Chondrogenic Medium [12] 
DMEM/Ham’s F12 
10% FBS 
1% pen-strep 
DMEM:Ham’s F12 
1% pen-strep 
33 μM biotin 
17 μM pantothenate 
10 μg/mL transferrin 
100 nM cortisol 
66 nM insulin 
1 nM triiodothryonine 
0.25 mM 
isobutylmethylxanthine * 
1 μg/mL troglitazone * 
DMEM:Ham’s F12 
10% FBS  
1% pen-strep 
50 μM ascorbic acid  
6.25 μg/mL insulin  
100 nM dexamethasone  
10 ng/mL TGF-β1 (R&D 
Systems, CAT#: 100-B-001)  
 
3.3.7 Adipogenic Differentiation Study 
Adipogenic differentiation was assessed at 14 days by quantitative measurement of glycerol-3-
phosphate dehydrogenase (GPDH) enzyme activity, IHC analysis to determine the presence of a 
hormonally regulated intracellular lipid protein (perilipin), and RT-qPCR analysis of adipogenic 
gene expression. As previously discussed, all experiments were repeated with cells isolated from 
3 different cell donors (N=3).  
3.3.7.1 GPDH Enzyme Activity 
GPDH is an enzyme that is upregulated during triglyceride synthesis and its activity can be used 
as a quantitative measure of adipogenic differentiation. Following published protocols [152], 
intracellular GPDH activity was measured using a spectrophotometric assay with a commercially 
available kit (Kamiya Biomedical Company, Tukwila, WA, United States) with normalization to 
the total cytosolic protein levels measured using the Bio-Rad protein assay with an albumin 
standard (Bio-Rad Laboratories Inc., Hercules, CA). GPDH activity was measured in triplicate 
samples for each cell donor (n=3, N=3) at an absorbance of 450 nm using a CLARIOstar® 
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spectrophotometer (BMG Labtech, Ortenberg, Germany). The activity required to oxidize 1 µM 
of NADH in 1 minute was defined as one unit of GPDH activity. 
3.3.7.2 Immunohistochemical Analysis of Perilipin Expression 
ECM+ASC and ASC-alone aggregates (n=3, N=3), were fixed in 4% PFA overnight, and 
processed at Robart’s Molecular Pathology laboratory. The fixed tissues were embedded in 
paraffin, sectioned (7 µm thickness) onto Superfrost® Plus microscope slides (Fisher Scientific, 
Ottawa, ON, Canada), and allowed to set overnight at room temperature before use. The sections 
were deparaffinized in 100% xylene, followed by rehydration in an ethanol series, and finally 
dH2O. The slides were subjected to antigen retrieval using DAKO citrate buffer, rinsed in TBS 
containing 0.025% Triton X-100, and blocked with 10% goat serum for 1 hour. The samples 
were then incubated in rabbit polyclonal anti-perilipin (ab3526, Abcam) diluted to 1:500 in TBS 
with 1% BSA solution overnight. Following this, the sections were rinsed with TBS and 
incubated in Dylight® 650 fluorescent goat anti-rabbit IgG secondary antibody (ab96902, 
Abcam) diluted to 1 µg/mL in TBS with 1% BSA for one hour at room temperature. The 
sections were rinsed, and mounted with DAPI mounting medium for imaging with an Evos FL 
cell imaging system (Thermo Fisher Scientific, Ottawa, ON, Canada). 
3.3.7.3 RT-qPCR Analysis of Adipogenic Gene Expression 
RT-qPCR analysis was performed using TaqMan® Gene Expression Assays to assess the 
expression of the adipogenic markers PPAR (Hs00234592_m1), lipoprotein lipase (LPL) 
(Hs00173452_m1) and adiponectin (Hs00905917_m1) in the induced samples cultured in 
adipogenic differentiation medium for 14 days, with IP08 (Hs00183533_m1) and GAPDH 
(Hs02758991_g1) included as the housekeeping genes (based on previous validation in the Flynn 
lab). To isolate sufficient RNA, 4 aggregates for each experimental group were pooled together. 
For RNA extraction, the pooled aggregate samples were immersed in 1 mL Trizol® Reagent 
(Invitrogen, Burlington, Canada), sonicated, and incubated at room temperature for 5 minutes. 
200 µL of chloroform (Sigma C7559) was added to the samples, which were vortexed and 
incubated at room temperature for 5 minutes, and then centrifuged at 12,000 x g for 15 minutes 
at 4°C. The upper aqueous phase was transferred to a new 1.5 mL tube, and an equal volume of 
chloroform:isoamyl alcohol (49:1) (Sigma C0549) was added to each tube. The samples were 
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vortexed and then centrifuged at 12,000 x g for 15 minutes at 4°C. Once more, the upper aqueous 
layer was transferred to a new 1.5 mL tube and an equal volume of 100% isopropanol was 
added. The samples were then inverted to mix, incubated at room temperature for 10 minutes, 
and centrifuged at 12,000 x g for 10 minutes at 4°C. The supernatant was removed and the RNA 
pellet was resuspended in 22 µL of molecular grade water. The concentration and purity of the 
RNA was measured using a NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific, 
Ottawa, ON, Canada).  
All samples were subjected to DNase digestion using a TURBO DNA-free kit™ (abmion 
AM1907, Life Technologies, Carlsbad, California) following the manufacturer’s instructions. 
First strand cDNA synthesis was then performed using the iScript™ kit (Bio-Rad 170-8840, 
Mississauga, ON, Canada) following manufacturer protocols with 250 ng of input RNA. Reverse 
transcription was carried out in a total reaction volume of 20 µL, consisting of iScript supermix 
or no-RT control, and 16 µL of RNA diluted in nuclease-free water. The reaction was carried out 
in Bio-Rad C1000 Touch Thermal Cycler (Bio-Rad Laboratories Inc., Hercules, California) with 
the following conditions: 5 minutes at 25˚C, 30 minutes at 42˚C, 5 minutes at 85˚C, and then 
cooling to 4˚C. 
For the PCR amplification, 5 µL of TaqMan® Universal Master Mix II, 3.5 µL of nuclease-free, 
molecular grade water, and 0.5 µL of primer were combined in each well. 1 µL of cDNA was 
added to each well and the reaction was carried out using a CFX384 Touch™ Real-Time PCR 
Detection System (Bio-Rad Laboratories Inc., Hercules, California). The conditions were as 
follows: 2 minutes at 50˚C, 20 s at 95˚C, and then 40 cycles of 3 s at 95˚C (denature) and 30 s at 
60˚C (anneal/extend). No reverse transcriptase and no template controls were included on every 
plate, and all samples were analyzed in triplicate. The results were analyzed using the ∆∆Ct 
method [204], with the ASC-alone induced group as the calibrator.  
3.3.8 Chondrogenic Differentiation Study 
Chondrogenic differentiation was assessed at 28 days by IHC of chondrogenic extracellular 
matrix proteins (collagen I and collagen II), histological analysis of GAG accumulation (safranin 
o), and RT-qPCR analysis of chondrogenic gene expression. As previously discussed, 
experiments were repeated with cells isolated from 3 different cell donors (N=3).   
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3.3.8.1 Immunohistochemical Analysis of Collagen II/I Expression 
IHC analysis was performed to qualitatively assess the levels of collagen II and collagen I 
expression in the ASC+ECM and ASC-alone aggregates (n=3, N=3), following the methods 
described in section 3.3.4. 
3.3.8.2 Histological Analysis of GAG Accumulation 
Safranin O staining was performed to qualitatively assess GAG accumulation in the ASC+ECM 
and ASC-alone aggregates (n=2, N=3), following the methods described in section 3.3.4. 
3.3.8.3 RT-qPCR Analysis of Chondrogenic Gene Expression 
RT-qPCR analysis was performed to assess the expression of the chondrogenic markers SOX9 
(Hs0100343_g1), cartilage oligomeric matrix protein (COMP) (Hs00164359_m1), and aggrecan 
(Hs00153936_m1) in the induced samples cultured in chondrogenic differentiation medium for 
28 days, with UBC (Hs01871556_s1) and RPL13A (Hs04194366_g1) included as the 
housekeeping genes (based on previous validation in the Flynn lab). To isolate sufficient RNA, 4 
aggregates for each experimental group were pooled together. The samples were analyzed 
following the methods for RNA isolation, cDNA synthesis and PCR amplification described in 
section 3.3.7.4. 
3.3.8.4 Statistical Analysis 
Statistical analyses were performed using GraphPad Prism 6 Software by one-way or two-way 
ANOVA with Tukey's post-hoc comparison of means. All data values are expressed as a mean ± 
standard deviation and significant differences considered when p< 0.05.  
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Chapter 4 
4 Results and Discussion 
4.1 Objective 1: Tissue Procurement and Decellularization 
4.1.1  Adipose Tissue Decellularization 
Adipose tissue was decellularized using established protocols in the Flynn lab [9]. During 
processing, the adipose tissue gradually transitioned into a white, highly-hydrated matrix (Figure 
4.1), consistent with previous findings demonstrating effective cell and lipid extraction [9]. 
 
 Figure 4.1 Macroscopic image of human adipose tissue (a) before and (b) after 
decellularization. 
4.1.2 Cartilage Tissue Decellularization 
Masson’s trichrome and safranin O/fast green staining was performed to compare the tissue 
structure and composition (Figure 4.2) following decellularization with two initial cartilage 
decellularization protocols adapted from Xu et al. [136]. DAPI staining was used to identify the 
presence of residual nuclei in the processed tissues. These protocols, which involved 72 hours 
enzymatic extraction with trypsin, DNase and RNase, demonstrated notable changes in the ECM 
composition, including qualitatively reduced GAG content, shown in red in the safranin O/fast 
green stained sections, with no GAG staining visualized in the samples treated with Protocol 1 B. 
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Further, the decellularization processes also appeared to negatively impact the tissue integrity as 
the samples were easily torn during sectioning, particularly for those treated with Protocol 1B. 
DAPI staining revealed the presence of a large number of residual nuclei in the tissues processed 
with Protocol 1A, while no positive nuclear staining was visualized in the samples treated with 
Protocol 1B. As the goal was to identify a decellularization protocol that effectively extracted 
cellular components while causing minimal changes to the ECM structure and composition, 
these findings prompted further investigation into alternative decellularization protocols.  
 
Figure 4.2 Representative histological results of the initial cartilage decellularization 
protocols in comparison to native cartilage controls.  The first column represents Masson’s 
trichrome stains where the cell nuclei appear black and collagen is blue. The second column 
represents safranin O/fast green staining. GAGs appear red and collagen appears blue/green. In 
the third column, DAPI staining shows cell nuclei in blue. Scale bars represent 100 m. 
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Three alternate decellularization protocols based on the work of Woods and Grazter [201] were 
tested using TBP or detergent (Figure 4.3), along with a shorter 5-hour DNase and RNase 
treatment. From the Masson’s trichrome, safranin O, and DAPI staining, Protocol 2A, comprised 
of 1% Triton X-100 treatment followed by 1% TBP extraction (Triton X-100/TBP), showed the 
most promising results. The samples processed using this protocol had qualitatively enhanced 
GAG staining in comparison to Protocols 1A, 1B, 2B (Triton X-100/Triton X-100) and 2C 
(Triton X-100/SDC) and reduced nuclei staining as compared to Protocols 1A and 2B. Relative 
to the initial trials, the processed tissues were more robust and easier to handle. Following the 
results of the second decellularization trial, a slightly modified approach (Protocol 2D) was 
tested using 2% Triton X-100 and 1% TBP to establish if the number of nuclei could be reduced 
further by increasing the detergent concentration in the early stages of processing. Masson’s 
trichrome and DAPI staining revealed no detectable cell nuclei in the samples processed with 
this revised protocol, and demonstrated qualitatively better preservation of the collagen and 
GAG content in the ECM relative to the other protocols, with staining patterns similar to native 
cartilage. Therefore, based on histological analysis, the decellularization approach in Protocol 2D 
was chosen for all future experiments. 
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Figure 4.3. Representative histological results of the initial cartilage decellularization 
protocols in comparison to native cartilage controls.  The first column represents Masson’s 
trichrome stains where the cell nuclei appear black and collagen is blue. The second column 
represents safranin O/fast green staining (red = GAGs, blue/green = collagen). In the third 
column, residual nuclei are shown in blue. Scale bars represent 100 m. 
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4.2 Objective 2: Milling and Characterization of ECM Particles 
4.2.1 Particle Size Analysis 
Lyophilization and cryogenic milling of DAT and DCT yielded a heterogeneous distribution of 
particle sizes. The largest yield in terms of the mass of dry particles collected was between the 45 
µm and 125 µm sieves (Figure 4.4).  
 
Figure 4.4: Mass of particles generated through cryo-milling DAT or DCT and sorted by 
size through sieving.  Data presented reflects the results for three pooled donors per ECM 
source.  
The Mastersizer analysis confirmed that the majority of the particles were in the size range of 
less than 125 µm (Figure 4.5). As the particles analyzed with the Mastersizer were in a hydrated 
state and prone to agglomeration, the second peak within each trial was suspected to be 
associated with particle aggregates. The results of the Kolmogorov–Smirnov test with p < 0.05 
confirmed that the particle size distributions for the DAT and DCT particles were statistically 
equivalent. 
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Figure 4.5 Cryo-milled DAT and DCT particle size distribution analyzed using a laser 
diffraction particle size analyzer.  The data shown represents the average of three technical 
replicates (n=3) of the pooled ECM particles sourced from three donors. 
4.2.2 Scanning Electron Microscopy 
Based on the SEM images, both the DAT and DCT particles had an amorphous structure with 
some visible fibers at the surface (Figure 4.6). However, the images suggest that the DAT and 
DCT may have different microstructures that are distinct to each type of tissue. This could 
potentially alter cell-ECM interactions with regards to cell attachment, spreading, and 
differentiation [205]. Further, structural and compositional variations in the particles may have 
some impact on the properties of the cell aggregates with regards to stiffness and cell densities. 
However, further research would need to be done to evaluate these potential effects. 
  
48 
 
 
Figure 4.6 Representative SEM images of DAT and DCT particles at 700x and 1000x 
magnification.  
4.3 Objective 3: In Vitro Cell Culture Studies 
4.3.1 Flow Cytometry 
Flow cytometry results from three donors (Figure 4.7) demonstrated that the ASCs expressed 
markers consistent with the expected ASC immunophenotype. Positive markers CD90, CD44, 
CD29, CD73, and CD105 were expressed at high levels (>90%), and the negative markers 
CD31, CD45, and CD146 were expressed at levels less than 2%. This is consistent with the 
requirements for ASCs as outlined by the International Federation for Adipose Therapeutics 
(IFATS) and Science and the International Society for Cellular Therapy (ISCT) guidelines [54].  
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Figure 4.7: Representative histograms and average flow cytometry results of ASC marker 
expression at passage 1 (n=3, N=3). 
4.3.2 Validation of the Chondrogenic Differentiation Medium Formulation  
Since chondrogenesis requires close cell-cell contact in order to mimic the condensation process 
observed in native tissue formation during development [77], all in vitro culture studies were 
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carried out using the self-aggregation methods described in Section 3.3.3. The effects of two 
chondrogenic media formulations reported in the literature for inducing chondrogenesis of ASCs 
on cartilage ECM production were assessed [12][71]. A qualitatively higher ratio of collagen 
II:collagen I expression was observed in the ASC pellets cultured in the differentiation medium 
comprised of 89% DMEM/Ham’s F12, 10% FBS, 1% pen-strep, 37.5 µg/mL of ascorbate-2-
phosphate (A2P), 6.25 µg/mL insulin, 100 ng dexamethasone, and 10 ng/mL TGF-β1. A higher 
ratio of collagen II:collagen I is characteristic of cells undergoing chondrogenesis [206], [207]. 
The safranin O staining also demonstrated qualitatively more uniform and intense staining with 
this formulation, suggesting enhanced GAG accumulation (Figure 4.8) indicative of cells 
undergoing chondrogenesis. Based on these results indicating effective induction of ASC 
chondrogenesis, this chondrogenic medium formulation was used for all subsequent studies.  
 
 
 
Figure 4.8 Validation of chondrogenic media formulations.   ASC pellets stained for collagen 
II and I (red), with DAPI counterstaining (blue), after 28 days in culture (scale bars=100 µm) 
(n=2). Safranin O analysis showing GAG content (red) (scale bars=200 µm). Porcine auricular 
cartilage was used as a positive control.  
  
51 
 
4.3.3 Verification of ECM Incorporation Within the Cell Aggregates  
Masson’s trichrome staining was performed to confirm that the DAT or DCT particles were 
successfully integrated into the cell aggregates (Figure 4.9a, b) following the self-aggregation 
methods described in Section 3.3.3. It was confirmed that the ECM was incorporated into the 
aggregates, with a heterogeneous distribution. To further verify ECM incorporation, a pilot study 
was conducted in which the ECM particles were pre-labeled with an amine-reactive Alexa 
fluor 350 succinimidyl ester. Visualization with fluorescence microscopy confirmed that the 
DAT and DCT particles were heterogeneously incorporated into the aggregates (Figure 4.9c, d).  
 
Figure 4.9 Representative staining of cell-ECM aggregates formed with DAT and DCT 
particles.  Masson’s trichrome staining of a) DAT + ASC and b) DCT +ASC aggregates 
showing embedded ECM particles in dark blue, with examples highlighted with arrows. Scale 
bars represent 100 µm. Fluorescence microscopy of Alexa fluor-labeled ECM particles (blue) in 
c) DAT+ASC and d) DCT+ASC aggregates with SYTOX® orange (green) nuclear 
counterstaining. Scale bars represent 200 µm. 
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4.3.4 In Vitro Adipogenic Study 
As previously discussed, adipogenesis was assessed using analysis of GPDH enzyme activity, 
perilipin by IHC, and adipogenic gene expression by RT-qPCR.  
4.3.4.1 GPDH Results 
GPDH enzyme activity was measured as a quantitative assessment of adipogenic differentiation. 
For ASC donor 1 (age: 41, BMI: 28.8), the GPDH activity levels were quite low and no 
significant differences were observed between the groups (Figure 4.10a). It is interesting to note 
that this donor had the highest BMI, and previous studies have observed that decreased 
adipogenesis has been noted in donors with an increased BMI [41], [152]. Trends indicated that 
GPDH activity was higher in the induced groups when compared to the non-induced groups, as 
expected. The DAT+ASC induced group demonstrated the highest GPDH activity when 
compared to other conditions, suggesting that the DAT may be assisting with the differentiation 
toward the adipogenic lineage.  
GPDH activity levels for donor 2 (Age:19, BMI: 26.7) were higher, with significantly higher 
activity levels observed in the induced conditions as compared to the non-induced conditions for 
the DAT+ASC group (Figure 4.10b). The data suggests that incorporating either type of ECM 
had a beneficial effect on adipogenic enzyme activity in the 3-D aggregate cultures. Further, the 
DAT+ASC induced group showed significantly higher levels of GPDH activity as compared to 
all other groups, indicating that adipogenesis was enhanced in the aggregates incorporating the 
adipose-derived ECM. Interestingly, significantly higher levels of GPDH enzyme activity were 
observed in the DAT+ASC non-induced samples as compared to both ASC-alone conditions, 
suggesting that the DAT had an adipo-inductive effect. This is consistent with what has been 
reported in the literature, with previous studies demonstrating DAT has the potential to induce 
adipogenesis when combined with various culturing methods [9], [53], [125], [148]. 
Similar to donor 2, GPDH activity was upregulated in donor 3 (Age:40, BMI:23.5) for induced 
conditions when compared to the non-induced aggregates within the same group for DAT+ASC 
and DCT+ASC conditions. Further, DAT+ASC induced aggregates demonstrated the highest 
levels of GPDH activity (Figure 4.10c), which was significantly different than all other groups. 
All aggregates incorporating ECM showed increased GPDH activity as compared to the ASC-
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alone aggregates, suggesting that the addition of ECM in general, aids in adipogenic 
differentiation. In comparing the GPDH levels for the DAT+ASC non-induced group to the 
DCT+ASC not induced group and ASC-alone conditions, the findings again suggest that the 
adipose ECM had an inductive effect on ASC adipogenic differentiation.  
 
 
Figure 4.10 GPDH enzyme activity for (a) donor 1, (b) donor 2, and (c) donor 3 at 14 days 
after adipogenic induction.   DAT = DAT+ASC aggregates, DCT = DCT+ASC aggregates, 
ASC = ASC-alone aggregates. I = induced (adipogenic medium), NI = non-induced 
(proliferation medium). Data represents the mean  standard deviation (n=3).  * indicates 
statistically different from all groups (p <0.05). ** indicates statistically different from groups 
indicated. 
4.3.4.2  Immunohistochemistry 
Within mature adipocytes, the lipid droplet-cytoplasm interface is stabilized by the protein 
perilipin, which makes perilipin a direct indicator of intracellular lipid accumulation during 
adipogenesis [208]. Perilipin in pre-adipocytes will surround cell nuclei, while mature adipocytes 
will show positive staining surrounding the nuclei and on the surface of lipid droplets within the 
cell cytoplasm [208][150].  
Positive perilipin staining was visualized in the DAT+ASC induced condition for donor 1 
(Age:17, BMI: 27.5), as well as for the DCT+ASC induced condition. The perilipin staining 
demonstrated qualitatively more positive cells in the DAT+ASC induced condition (Figure 
4.11a). Moreover, the positive perilipin staining in this group also qualitatively showed that the 
cells appear to have a more mature phenotype, with larger intracellular lipid droplets in the cells. 
The staining pattern of this donor was most pronounced around the periphery of the aggregates, 
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suggesting that the outer cells were undergoing differentiation. It is speculated that nutrient 
diffusion may have played a role in this response. More specifically, the outermost cells will 
have enhanced access to nutrients and inductive factors in the media as compared to the cells 
within the core of the aggregates. This could lead to more bioactive cells at the periphery and 
explain the staining patterns seen.   
Perilipin was visualized with positive staining in cell donor 2 (Age:19, BMI:26.7) for the 
DAT+ASC and DCT+ASC induced conditions. Small rings can be seen around the cell nuclei in 
both induced groups incorporating ECM, suggesting that having some type of matrix 
incorporated into the aggregates is more beneficial than culturing the cells alone in a 3-D 
configuration. The staining was qualitatively more pronounced in the DAT+ASC induced 
condition, suggesting that the DAT may be more supportive of adipogenic differentiation than 
the DCT (Figure 4.11b).  
Interestingly, positive perilipin staining was visualized for all induced conditions for cell donor 3 
(Age:49, BMI:23.5), who also had the lowest BMI tested amongst donors. All three induced 
conditions had very obvious staining of perilipin positive cells around the exterior of the 
aggregates (Figure 4.11c). As discussed previously, it is speculated that this is due to the greater 
availability of nutrients and adipogenic supplements at the exterior surface of the aggregates. 
Interestingly, the DAT+ASC induced conditions not only demonstrated positive staining around 
the exterior of the aggregates, but also within the interior (Figure 4.12). This supports the 
previous findings that the DAT particles enhanced ASC adipogenic differentiation.  
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Figure 4.11 Representative IHC images of perilipin expression (red) with DAPI 
counterstaining (blue) for (a) donor 1, (b) donor 2, and (c) donor 3. Images shown were 
taken at the periphery of the aggregates. Scale bars=100 µm. 
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Figure 4.12 Representative IHC images of perilipin expression (red) with DAPI 
counterstaining (blue) for donor 3, DAT+ASC induced conditions at (a) 20x magnification 
and (b) 40x magnification.  Perilipin positive cells were observed in the interior of the cell-
ECM aggregates in this condition. Scale bars are equal to a) 200 µm and b) 100 µm. 
4.3.4.3 RT-qPCR Results 
Samples from a test run did not yield enough input RNA to allow for measurable readings in the 
non-induced conditions. Further, perilipin staining was also negative for the non-induced 
conditions, suggesting that intracellular lipid accumulation was minimal when the cells were 
maintained in proliferation medium. For these reasons, it was decided to focus the gene 
expression analysis on comparing the effects of incorporating the ECM on ASC adipogenesis 
under adipogenic differentiation conditions only.  
In analyzing the donor 1 samples, a trend of enhanced expression of the early adipogenic marker 
PPARϒ was noted in the DAT+ASC induced conditions (Figure 4.13a). Further, the mid-marker 
lipoprotein lipase (LPL) and late-marker adiponectin (AdipoQ) were significantly upregulated in 
the DAT+ASC conditions when compared to the DCT+ASC and ASC-alone at 14 days. These 
results corroborate the GPDH findings that the DAT has instructive effects on promoting ASC 
adipogenesis. This is consistent with previous results demonstrating that DAT provides an adipo-
conductive platform when incorporated into hydrogels and microcarriers [127], [125]. 
For donor 2 (Age:19, BMI:26.7), PPARϒ expression followed the trend seen with all markers in 
that expression was highest in the DAT+ASC induced conditions (Figure 4.13b), and was 
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significantly higher than the ASC-alone group. Similar to the GPDH and IHC results, the 
expression patterns for all three genes indicated that adipogenic marker expression was enhanced 
in the aggregates incorporating ECM. Further, significantly higher levels of LPL and AdipoQ 
expression were observed in the DAT+ASC group relative to all other conditions, suggesting 
that the adipose ECM enhanced ASC adipogenesis.  
While the average fold changes were lower, similar trends were seen for cell donor 3 (Age:49, 
BMI:23.5) with regards to gene expression (Figure 4.13c). The aggregates with ECM showed 
increased LPL and adiponectin expression when compared to the ASC-alone group, suggesting 
that the addition of ECM aids in differentiation. Moreover, significantly higher levels of 
expression of these two markers were observed in the DAT+ASC group, indicating that DAT 
may be superior to DCT for inducing adipogenic differentiation, and validating what was seen in 
both the GPDH enzyme activity assay and perilipin staining.  
 
Figure 4.13 Adipogenic gene expression at 14 days for cell (a) donor 1, (b) donor 2, and (c) 
donor 3.   Calibrated to ASC induced conditions. DAT = DAT+ASC aggregates, DCT = 
DCT+ASC aggregates, ASC = ASC-alone aggregates. I = induced (adipogenic medium). Data 
represents the mean  standard deviation (n=3* indicates statistically different from all groups (p 
<0.05). ** indicates statistically different from groups indicated. 
4.3.5 In Vitro Chondrogenic Study 
As previously discussed in Chapter 3, chondrogenesis was assessed using collagen II and 
collagen I IHC, safranin O staining of GAG accumulation, and RT-qPCR analysis of 
chondrogenic gene expression.  
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4.3.5.1 Immunohistochemistry and Histology 
It has been suggested in the literature that the proteins collagen I and II are upregulated during 
chondrogenesis as extracellular matrix is being produced by the ASCs [206]. An increased ratio 
of collagen II:collagen I is expected during chondrogenesis [179].  
Results from ASC donor 1 (age: 19, BMI: 26.7) demonstrated (Figure 4.14a) strong positive 
staining for collagen II in both DCT+ASC conditions, as well as low levels in the DAT+ASC 
and ASC-alone induced groups, suggesting that the cells were undergoing chondrogenesis.  
However, a limitation of the experimental design is that it is technically challenging to 
distinguish new ECM produced by the cells from the ECM within the embedded particles. Based 
on knowledge of the composition of adipose and cartilage ECM, it would be expected that the 
DAT particles would be comprised substantially of collagen I and the DCT particles of collagen 
II [112]. As such, it is difficult to assess how much of the collagen II in the DCT+ASC groups 
was synthesized by differentiating cells. It is worth noting that collagen II staining in the DCT 
aggregates was quite uniform, unlike the heterogeneous distribution of the particles in the 
aggregates seen in Figure 4.9. Based on the more homogenous staining, it is speculated that at 
least part of the collagen II detected was newly synthesized by the cells. IHC showed low levels 
of collagen I (Figure 4.15a) expression in all chondrogenic induced conditions, with no 
detectable expression in all non-induced controls.  
IHC for donor 2 (age:17, BMI: 27.5) demonstrates collagen II accumulation appears to be 
enhanced in all conditions when compared to donor 1. Literature suggests that differences in 
expression of collagen II and collagen I between trials may be attributed to donor variability 
[209]. Collagen II staining was observed in all conditions, with more intense staining found in 
the DCT+ASC groups, with a highly uniform staining pattern observed across the entire 
aggregate cross-section in the induced conditions (Figure 4.14b). Interestingly, both of the 
DAT+ASC groups also showed very uniform collagen II expression, suggesting that the cells 
were undergoing chondrogenic differentiation in the presence of the DAT.  In contrast, the ASC-
alone samples had qualitatively reduced collagen II expression in the induced conditions, as well 
as no detectable levels of collagen II in the non-induced conditions, suggesting that incorporating 
the ECM had a positive effect on ASC chondrogenesis. The collagen I staining results indicate 
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that the ASC-alone group cultured in chondrogenic medium had qualitatively enhanced collagen 
I expression (Figure 4.15b), consistent with a less differentiated phenotype.  
Collagen II staining for donor 3 (age: 50, BMI:29) was more pronounced for all induced 
conditions when compared to non-induced counterparts (Figure 4.14c), with the most intense 
staining seen in the DCT+ASC aggregates. The DAT+ASC induced group had qualitatively 
higher levels of expression as compared to the ASC-alone conditions, further supporting the 
previous findings that incorporating the ECM particles had a positive effect on the chondrogenic 
differentiation of the ASCs. Interestingly, when magnification was increased to 20X, induced 
conditions that included either DAT or DCT showed positive collagen II staining similar to 
native cartilage, with evidence of a possible pericellular matrix region around the cells (Figure 
4.16). For this cell donor, collagen I was detected in all groups, with qualitatively enhanced 
expression in the DCT induced and not induced conditions (Figure 4.15c).  
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Figure 4.14 Representative images of collagen II staining (red) with DAPI counterstaining 
(blue) from (a) donor 1, (b) donor 2, and (c) donor 3.  Scale bars = 100 µm. 
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Figure 4.15 Representative images of collagen I (red) staining with DAPI counterstaining 
(blue) from (a) donor 1, (b) donor 2 and, (c) donor 3.  Scale bars = 100 µm. 
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Figure 4.16 Representative 20X images of collagen II staining with DAPI counterstaining 
from donor 3.  Induced conditions with (a) native porcine auricular cartilage (b) DAT+ASC and 
(c) DCT+ASC groups. Scale bars = 100 µm. 
Safranin O staining was used to visualize GAG accumulation within the aggregates (Figure 
4.17a). Qualitatively darker staining was observed in the DCT+ASC induced condition than the 
other groups cultured in chondrogenic medium, which is suggestive of increased GAG content. It 
is worth noting that the aggregates cultured in the induced conditions from all donors were 
macroscopically larger than the non-induced controls, suggesting there may be enhanced ECM 
deposition in the cultures maintained in chondrogenic medium. This is supported by literature 
suggesting that factors such as TGF-β1 and A2P upregulate synthesis of cartilage-specific matrix 
containing GAGs and a higher ratio of collagen II:collagen I [78][179].  
For donors 2 (Figure 4.17b) and 3 (Figure 4.17c), safranin O staining suggested that induced 
conditions displayed consistently more homogenous, darker stains when compared to not 
induced conditions. This confirmed what was seen with collagen II and collagen I IHC staining. 
DCT+ASC conditions produced more intense and homogenous staining for GAG accumulation 
when compared to the DAT+ASC conditions. The combination of data from collagen II/collagen 
I IHC and safranin O staining was suggestive of enhanced chondrogenic ECM accumulation in 
the DCT+ASC group relative to either DAT+ASCs or ASC-alone.  
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Figure 4.17 Representative images of safranin O staining for (a) donor 1, (b) donor 2, and 
(c) donor 3.  Safranin O staining of GAG content (red) present in cell aggregates. Scale bars = 
100 µm. 
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4.3.5.2 RT-qPCR Results 
To complement the qualitative staining results, RT-qPCR analysis was performed to assess the 
expression of the chondrogenic markers SOX9, COMP, and aggrecan in the induced samples 
cultured in chondrogenic medium, with UBC and RPL13A included as the housekeeping genes.  
The gene expression results showed very consistent patterns across all three donors (Figure 
4.18). Results from donor 1 (Figure 4.18a) show a trend for enhanced SOX9 gene expression and 
significantly higher levels of AGG gene expression in the DCT+ASC experimental group as 
compared to the other two groups. Interestingly, the DAT+ASC group demonstrated significant 
upregulation of the COMP gene as compared to the other conditions. One possibility is that 
COMP gene expression may have peaked earlier in the DCT+ASC group when compared to the 
DAT+ASC conditions, causing the results seen. A similar study saw chondrogenic genes 
upregulated after one week in studies combining decellularized cartilage with bone-marrow-
derived stem cells (bMSCs) [210]. While RT-qPCR quantitatively measures gene expression, it 
only provides information about the levels of gene expression at the point in time when the 
samples were processed. Given that gene expression patterns can vary considerably as 
differentiation progresses, average fold changes would very likely be different if the samples 
were assessed at an earlier or later time point. Since COMP has been reported as an early/mid 
marker and AGG as a late-stage marker of human mesenchymal stem cell (MSC) 
chondrogenesis [211], it is possible that the DCT+ASC group had a more differentiated 
phenotype, although further studies with additional time points and markers would be required to 
verify this interpretation. 
While the average fold change values were generally higher, in comparing the groups, the gene 
expression patterns for donor 2 were very similar to donor 1. DAT induced conditions for donor 
2 (Figure 4.18b) show a trend of enhanced SOX9 expression in both groups that incorporate 
ECM. Two-way ANOVA results indicate significantly elevated COMP expression in the 
DAT+ASC group relative to all other conditions, as well as in the DCT+ASC group as compared 
to the ASC-alone samples. Additionally, similar to donor 1, AGG was significantly upregulated 
in the DCT+ASC aggregates when compared to both the DAT+ASC and ASC-alone groups.  
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Results from the RT-qPCR analysis for donor 3 (Figure 4.18c) were very similar to those of 
donor 1. Again, trends indicated enhanced SOX9 expression in the DCT+ASC group. Similar to 
the other donors, results indicated that the DAT+ASC group showed elevated COMP expression 
when compared to the DCT+ASC and ASC-alone groups, and that the DCT+ASC group had 
enhanced COMP expression when compared to the ASC-alone group. This suggests that the 
addition of ECM is superior to ASC-alone for promoting chondrogenic differentiation. 
Moreover, AGG gene expression was again significantly enhanced in the DCT+ASC group, 
potentially suggestive of a more differentiated phenotype. 
 
Figure 4.18 Chondrogenic gene expression at 28 days for (a) cell donor 1, (b) donor 2 and, 
(c) donor 3.   Calibrated to ASC induced conditions. DAT = DAT+ASC aggregates, DCT = 
DCT+ASC aggregates, ASC = ASC-alone aggregates. I = induced (adipogenic medium). 
Data represents the mean  standard deviation (n=3).  * indicates statistically different from 
all groups (p <0.05). ** indicates statistically different from groups indicated. 
Results and trends from this study suggest that incorporating ECM promotes chondrogenic gene 
expression relative to ASC-alone, which is consistent with the IHC staining results. A limitation 
of this study is that only one time point was analyzed. As discussed, it would be interesting to 
look at a time series in future studies to analyze changes in gene expression among the different 
conditions. The COMP protein plays an important role in growth, division, cell attachment, and 
apoptosis in cartilage tissue [72]. This non-collagenous protein has been shown to interact with 
SOX9 to promote chondrogenic activity of MSCs from cellular condensation to terminal 
differentiation [72], [211]. COMP is upregulated in chondroprogenitors through to terminal 
differentiation [72], while AGG is typically regarded as a mature chondrocyte matrix gene [212]. 
One study showed that COMP levels in human MSCs induced to differentiate in 3-D alginate 
gels peaked around 12 days, while AGG levels peaked beyond 24 days, raising the need for a 
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time series including time points at 7 and 14 days [211]. Additionally, other late expression 
markers such as lubricin (PRG4) and matrilin-1, as well as the hypertrophic marker collagen X, 
could be assessed at 28 days to corroborate the speculations made above.  
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Chapter 5 
5 Conclusions 
As the emerging field of tissue engineering and regenerative medicine continues to expand upon 
the knowledge of the extracellular matrix (ECM), it becomes apparent that there is greater need 
for tissue-specific cell-based therapies. Tissues such as cartilage have a limited regenerative 
capacity and require assistance in order to return functionality back to the tissue. Each tissue 
within the body has a specific structure and function, providing a rationale for the use of tissue-
specific scaffolds for regenerative purposes. While research has investigated the effects of tissue-
specific biomaterials and scaffolds on differentiation, few studies to date have focused on the 
effects of multiple ECM sources on directing the lineage-specific differentiation of stem cells 
[8], [148]. This begs the question, do tissues require a specific ECM or will the addition of any 
type of ECM aid in the differentiation of stem/stromal cells? Incorporating decellularized ECM 
sourced from adipose tissue or cartilage into cell aggregate cultures provides insight into the 
potential importance of using tissue-specific ECM to guide differentiation and/or to act as a 
natural scaffold for the regeneration of adipose or cartilage tissue. Decellularized matrices 
represent an attractive biomaterial for 3-D scaffolds because they retain a complex mixture of 
functional and structural proteins from natural tissue sources [82].  
Detergent-free methods of decellularization had been previously established in order to fabricate 
decellularized adipose tissue (DAT). In order to examine the effects of DAT and decellularized 
cartilage tissue (DCT), an examination of various cartilage decellularization protocols based on 
the literature was required. Successful decellularization of the ECM required removal of cellular 
materials while maintaining the integrity of the native tissue. Several different protocols were 
tested. A protocol was developed that successfully removed cellular material while 
macroscopically preserving the collagen and GAG within the ECM, which involved: repeated 
freeze/thaw cycles, osmotic cell lysis through washes in hypotonic Tris buffers, 5-hour 
enzymatic digestion with trypsin/EDTA, and rinses in a high salt buffer containing 2% Triton X-
100, followed by 1% tributyl-phosphate (TBP). Successful decellularization of cartilage was 
achieved through removal of cellular contents as visualized by Masson’s trichrome and DAPI 
staining. GAG retention was also qualitatively maintained through the use of this protocol. 
  
68 
 
DAT and DCT were lyophilized and milled into ECM particles. The particles were then sorted 
by size, collecting those captured between 45 µm and 125 µm screens. The resulting particles 
were characterized using dynamic light scattering and scanning electron microscopy. It was 
concluded that a heterogeneous mixture of particle sizes was achieved through the process, with 
some structural differences noted between the two types of ECM.  
Finally, in vitro culture studies were conducted to assess the potential effects of the tissue-
specific ECM on the lineage-specific differentiation of human adipose-derived stem/stromal cells 
(ASCs). First, chondrogenic media formulations were tested and culture methods were 
established for creating the cell-ECM aggregates. Subsequently, in vitro cell culture studies were 
conducted to investigate adipogenesis and chondrogenesis of aggregates comprised of (i) 
DAT+ASCs, (ii) DCT+ASCs, and (iii) ASC-alone, cultured in both differentiation and 
proliferation media.  
The results demonstrated that the addition of ECM generally improved differentiation for both 
adipogenesis and chondrogenesis, as demonstrated by analysis of protein expression and 
confirmed with RT-qPCR. Both adipogenic and chondrogenic markers were upregulated in 
conditions containing ECM when compared to the ASC-alone groups.  
Adipogenesis was assessed by glycerol-3-phosphate dehydrogenase (GPDH) activity, perilipin 
immunohistochemistry (IHC) and RT-qPCR. The GPDH results consistently demonstrated that 
GPDH expression was higher in all induced aggregates when compared to the corresponding 
non-induced controls. The DAT+ASC groups consistently showed the highest levels of GPDH 
activity, suggesting that incorporating the DAT enhanced adipogenesis relative to either the 
DCT+ASCs or ASC-alone. Perilipin results confirmed this finding, as the DAT induced 
conditions consistently stained positive for perilipin, with the cells qualitatively having a more 
mature phenotype associated with larger intracellular lipid droplets. For the third cell donor, 
positive perilipin staining was visualized around the edges of the aggregates for all induced 
conditions. However, the DAT induced aggregates were the only group that also demonstrated 
perilipin staining within the interior of the aggregates in this set of samples. RT-qPCR results 
consistently demonstrated that the DAT+ASC induced conditions had larger fold changes for the 
adipogenic markers LPL and adiponectin. Taken together, the findings support that the DAT has 
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adipo-inductive and adipo-conductive properties and is superior to either the DCT or ASCs alone 
for inducing adipogenesis within 3-D aggregate cultures.  
Chondrogenesis was assessed by comparing collagen II and collagen I expression, as higher 
expression of collagen II is related to increased chondrogenic activity. A limitation of this study 
was that it was difficult to discern newly synthesized matrix from the ECM in the particles that 
were incorporated into the aggregates. IHC results demonstrated once again that the inclusion of 
ECM had a positive effect on differentiation relative to culturing the ASCs alone. The 
DCT+ASC samples consistently demonstrated more intense fluorescent staining for collagen II 
than the other conditions, but as mentioned previously, it was difficult to differentiate between 
the ECM particles and newly-synthesized matrix within the aggregates. Safranin O staining 
demonstrated darker staining in all induced conditions, and when combined with the IHC results, 
supported the conclusion that incorporating either type of ECM in the aggregates enhanced 
cartilage matrix synthesis. The uniformity of the response may suggest that incorporating DCT 
may be superior to DAT in terms of collagen II/collagen I production, but further studies would 
be required to verify this interpretation. Results of RT-qPCR studies showed trends that the 
DCT+ASC group had enhanced SOX9 expression at 28 days when compared to the other 
groups. Further, RT-qPCR results for all three donors show that COMP gene expression was 
upregulated for both the DAT+ASC and DCT+ASC groups when compared to ASC-alone at 28-
days, with significantly higher expression in the DAT+ASC group. Additional time points may 
demonstrate different results at 7 and 14 days, as several studies have seen SOX9 and COMP 
levels peak between 6 and 14 days [1], [211]. Additionally, all donors demonstrated that AGG 
gene expression was upregulated in DCT+ASCs when compared to either DAT+ASCs or ASC-
alone, and supports the theory that the DCT+ASC aggregates may be more terminally 
differentiated than other groups. Additional gene expression studies would help to confirm this 
hypothesis.  
Towards the development of tissue-specific cell-based strategies for tissue engineering, the data 
obtained highlights the potential effects that the ECM has on the differentiation of ASCs and 
demonstrates a promising use of decellularized ECM materials for the development of tissue-
specific instructive platforms for directing mesenchymal stem/stromal cell (MSC) differentiation. 
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5.1 Future Recommendations 
Short-term goals to build from the work presented in this thesis include further application of 
fluorescent labeling of the DAT and DCT particles prior to incorporation in the cell-ECM 
aggregates to assist in distinguishing the newly-synthesized ECM from the ECM particles during 
IHC analyses. This would give a better indication of collagen II and collagen I production, 
particularly in the DCT+ASC conditions. It would also be interesting to look at chondrogenic 
differentiation at earlier time points of 7 and 14 days to see how gene expression changes in the 
earlier stages of chondrogenesis. One study showed increased gene expression levels in cell-
ECM aggregates incorporating DCT at 24 hours and 7 days [1]. It would also be beneficial to 
look at wider array of chondrogenic genes such as SOX5, SOX6, COLII, lubricin, matrilin-1 and 
COLX. A more quantitative assay such as the Blyscan™ sulphated GAG assay kit or DMMB 
assay could also be done to give more quantitative results to complement the safranin O staining. 
It would also be worthwhile to repeat the adipogenic studies to further validate trends with 
additional cell donors. This would clarify the results of this study and may provide more insight 
into whether there are differences between the aggregates incorporating DAT and DCT.  
Porcine auricular cartilage was used as an ECM source for this study as a proof of concept. It 
would be interesting to examine a different cartilage source, such as fibrocartilage or hyaline 
cartilage, to see if the tissue source has an impact on the chondrogenic differentiation of the 
ASCs. Additionally, it would be worth exploring human cartilage as a source of DCT, although 
this would be more challenging to obtain. Expanding on the overall strategy for this project, it 
would be worth examining decellularization of other tissues such as bone, skin, and muscle. 
Using similar methods, ASCs and ECM could be combined and differentiated towards the 
osteogenic, endothelial, and myogenic lineages in order to gain a broader understanding of the 
potential effects of tissue-specific ECM.  
Alternatively, it would be interesting to investigate the manipulation of the DCT as a scaffolding 
material. If the DCT were enzymatically digested, this could allow for the fabrication of ECM-
dervied foams, microcarriers, and sheets. These alternative scaffold formats would allow for 
better control of the architecture of the scaffold and potentially better control of the distribution 
of ECM compared to the cells. This was a limitation in this project that could be addressed 
through the manipulation of the ECM materials. More specifically, it was difficult to control the 
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distribution of the ECM and the cells, leading to heterogeneous cell-ECM aggregates. Using 
ECM-derived microcarriers, for example, might solve this problem, and would still allow for the 
3-D culture conditions required for chondrogenesis. The porosity could also be controlled, which 
may aid in cell infiltration into the scaffold, which is a common problem with current cartilage 
tissue engineering methods [123]. 
In terms of long-term goals for the work presented in this thesis, incorporating the ECM particles 
into other materials, such as hydrogels would be an interesting way to examine the effects the 
ECM has on differentiation where nutrient availability could be limited. Some recent studies 
have suggested that ECM-derived materials can provide an instructive microenvironment for 
directing stem/stromal cell fate [8], [192]. ECM particles could also be incorporated into 
injectables, to develop clinically-translational cell-based therapies using the ECM as an 
instructive component to direct stem cell differentiation. Testing these results with various 
decellularized tissues to examine the tissue-specific effects could be first accomplished in vitro. 
In terms of in vivo work, murine models can be used to examine the effects of tissue-specific 
cell-ECM therapies. Incorporating various scaffold types into different tissues can aid in the 
understanding of how the ECM can affect cellular fate in vivo. Additionally, it should be 
proposed that cell-based therapies continue to incorporate naturally-derived ECM into 
experiments, as this has shown promise for aiding the proliferation and differentiation of 
stem/stromal cells both in vitro and in vivo.  
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Appendix A 
 
Figure A.1: Immunohistochemical of collagen II and collagen I (red) staining with DAPI 
counterstaining (blue) on (a) porcine cartilage (COL II) and skin (COL I) and, (b) with no 
primary controls.  Scale bars = 100 µm (n=2). 
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Figure A 2: Immunohistochemical of perilipin (red) staining with DAPI counterstaining 
(blue) on (a) murine adipose tissue and, (b) with no primary controls.  Scale bars = 100 µm 
(n=2). 
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